[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 340
1. Weigert O, Unterhalt M, Hiddemann W, Dreyling M: Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma; 2009 Dec;50(12):1937-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma: state-of-the-art management and future perspective.
  • Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression.
  • Most patients present with advanced stage disease, often with extranodal dissemination, and typically pursue an aggressive clinical course.
  • Recent improvement has been achieved by the successful introduction of monoclonal antibodies and dose-intensified approaches including autologous stem cell transplantation strategies.
  • However, with the exception of allogeneic hematopoietic stem cell transplantation, current treatment approaches are not curative and the corresponding survival curve is characterized by a relatively steep and continuous decline, with a median survival of about 4 years and <15% long-term survivors.
  • Despite its rarity, MCL is of particular clinical and scientific interest by providing a paradigm for neoplasms with dysregulated control of cell cycle machinery and impaired apoptotic pathways.
  • [MeSH-major] Drug Therapy / methods. Lymphoma, Mantle-Cell / pathology. Lymphoma, Mantle-Cell / therapy. Stem Cell Transplantation / methods


2. Lin HN, Liu CY, Hong YC, Pai JT, Yang CF, Yu YB, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Tzeng CH, Chen PM: Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma; 2010 Dec;51(12):2208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis.
  • Among all patients, 67.7% were Ann Arbor stage III or IV, 58.1% presented with B symptoms, 48.4% had hypoalbuminenia (<35 g/L), and 63.3% had elevated lactate dehydrogenase (LDH) at diagnosis.
  • In multivariate analysis, initial presentation with fever (p = 0.035), advanced stage (p = 0.024), and failure to achieve CR (p = 0.029) were independent adverse factors associated with poorer OS.
  • Despite the prognosis being generally poor, patients with AITL should be treated with the goal of achieving CR, regardless of anthracycline- or non-anthracycline-based chemotherapy.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2011 Jan;52(1):1-2 [21133725.001]
  • (PMID = 21054150.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Sun XF, Zhen ZJ, Xia Y, Yang QY, Wang ZH, Ling JY: [The clinical features of B cell lymphoblastic lymphoma and outcomes after BFM-90 regimen therapy]. Zhonghua Xue Ye Xue Za Zhi; 2006 Oct;27(10):649-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical features of B cell lymphoblastic lymphoma and outcomes after BFM-90 regimen therapy].
  • OBJECTIVE: To analyse the clinical features of patients with B cell lymphoblastic lymphoma(BCLL) and the outcomes after modified BFM-90 protocol therapy.
  • METHODS: The clinical features of 14 patients with BCLL were analysed, and compared with that of T cell lymphoblastic lymphoma in the same period.
  • One case was in stage I , 2 stage III and 11 stage IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343193.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Han S, Chen Y, Ge X, Zhang M, Wang J, Zhao Q, He J, Wang Z: Epidemiology and cost analysis for patients with oral cancer in a university hospital in China. BMC Public Health; 2010;10:196
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidemical characteristics are as follows: female/male 176/280; squamous cell carcinoma (SCC)/adenocarcinoma/sarcoma/lymphoma/other types 246/127/40/27/16; stage I/II/III/IV 90/148/103/115; smoker/non-smoker 136/320; rural/urban patients 82/374.
  • The CPP and MHD of patients in late clinical stage were higher than that of patient in early stage.
  • Lack of medicare, smoking habit, late clinical stage and SCC are the high economic factors for patient medical cost.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Maxillofac Surg. 2003 Jul;61(7):751-8 [12856245.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Feb;129(2):219-28 [12578453.001]
  • [Cites] J Am Dent Assoc. 1972 Sep;85(3):637-40 [4505593.001]
  • [Cites] N Engl J Med. 1982 May 13;306(19):1151-5 [7040958.001]
  • [Cites] Oper Dent. 1989 Summer;14(3):114-20 [2637996.001]
  • [Cites] J Clin Anesth. 1994 Sep-Oct;6(5):357-63 [7986506.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):745-53 [9469366.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 [9811312.001]
  • [Cites] Support Care Cancer. 2005 Jan;13(1):32-41 [15549427.001]
  • [Cites] Oncologist. 2006 Jun;11(6):590-601 [16794238.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jul;102(1):67-76 [16831675.001]
  • [Cites] Mayo Clin Proc. 2007 Jul;82(7):878-87 [17605971.001]
  • [Cites] Head Neck. 2008 Feb;30(2):178-86 [17694558.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2008 Apr;16(2):113-6 [18327029.001]
  • [Cites] J Can Dent Assoc. 2008 Apr;74(3):269-72 [18387267.001]
  • [Cites] J Can Dent Assoc. 2008 Apr;74(3):245 [18401902.001]
  • [Cites] Oral Dis. 2008 May;14(4):314-9 [18449960.001]
  • [Cites] J Oral Maxillofac Surg. 2008 Aug;66(8):1570-9 [18634942.001]
  • [Cites] Stomatologiia (Mosk). 2008;87(6):21-3 [19156101.001]
  • [Cites] Oral Oncol. 2009 Nov;45(11):958-62 [19502101.001]
  • [Cites] Br Dent J. 2000 Mar 11;188(5):262-5 [10758688.001]
  • [Cites] J Dent Educ. 2001 Apr;65(4):328-39 [11336118.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):149-55 [12210442.001]
  • [Cites] BMC Public Health. 2002 Jul 19;2:12 [12133170.001]
  • [Cites] J Can Dent Assoc. 2004 May;70(5):302-4 [15132812.001]
  • (PMID = 20398380.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2864212
  •  go-up   go-down


5. Jun HJ, Kim WS, Yang JH, Yi SY, Ko YH, Lee J, Jung CW, Kang SW, Park K: Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma. Cancer Res Treat; 2007 Mar;39(1):40-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma.
  • The pathologic diagnosis of the radical orchiectomy specimen was peripheral T-cell lymphoma, unspecified (PTCL-u).
  • According to the Ann Arbor staging system, his initial stage was III because of the right nasopharyngeal involvement.
  • Although the patient received intensive chemotherapy with autologous hematopoietic stem cell transplantation, he ultimately died of leptomeningeal seeding.
  • Because both the central nervous system (CNS) and the orbit are sanctuary sites for chemotherapy, orbital infiltration of lymphoma should prompt physicians to evaluate involvement of the CNS and to consider performing prophylactic intrathecal chemotherapy as a treatment option.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Histopathology. 1989 Aug;15(2):147-56 [2777217.001]
  • [Cites] Br J Urol. 1984 Oct;56(5):525-30 [6398719.001]
  • [Cites] Arch Ophthalmol. 1984 Mar;102(3):399-402 [6608342.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • (PMID = 19746228.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739356
  • [Keywords] NOTNLM ; Eye neoplasm / Non-Hodgkin's lymphoma / T cell lymphoma / Testes
  •  go-up   go-down


6. Kim JH, Lee JH, Lee J, Oh SO, Chang DK, Rhee PL, Kim JJ, Rhee JC, Lee J, Kim WS, Ko YH: Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings. Endoscopy; 2007 Feb;39(2):156-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings.
  • BACKGROUND AND STUDY AIMS: Primary NK-/T-cell lymphoma of the gastrointestinal tract is a very rare disease with a poor prognosis.
  • The aim of this study was to determine the clinical and endoscopic characteristics of patients with primary gastrointestinal NK-/T-cell lymphoma.
  • PATIENTS AND METHODS: The clinical features of 14 patients with primary gastrointestinal NK-/T-cell lymphoma and the endoscopic findings in 11 of these patients were reviewed.
  • RESULTS: The initial presenting symptoms of primary gastrointestinal NK-/T-cell lymphoma were gastrointestinal bleeding (n = 6, 42%), abdominal pain (n = 4, 29%), and epigastric soreness (n = 4, 29%).
  • The disease was at an advanced stage at the time of diagnosis: stage II in 5 patients (36%); stage III in 4 (28%); and stage IV in 5 (36%).
  • CONCLUSIONS: Primary gastrointestinal NK-/T-cell lymphoma was endoscopically characterized by superficial/erosive, ulcerative, or ulceroinfiltrative lesions without fungating mass.
  • [MeSH-major] Endoscopy, Gastrointestinal. Gastrointestinal Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657701.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Vural F, Ocakcı S, Dubova S, Akad Soyer N, Saydam G, Çağırgan S, Anacak Y, Hekimgil M, Dönmez A, Tombuloğlu M: Gastric and non-gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: A single-center experience. Turk J Haematol; 2007 Jun 5;24(2):57-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric and non-gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: A single-center experience.
  • Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) is a distinct lymphoma with specific clinical and pathological features that occurs in diverse anatomic locations.
  • We studied 23 patients with histologically confirmed diagnosis of MALT lymphomas (12 with gastric, 11 with non-gastric localization) treated during the past 13 years.
  • 16 patients (70%) with stage I and II, 7 patients (30%) with stage III and IV were admitted.
  • There was no difference between gastric and non-gastric MALT lymphomas when compared with sex, age, ECOG performance status, stage of the disease.
  • All the patients are alive with a median 33 months (range 8-153 months) of follow-up and the 5- year PFS in gastric lymphoma and non-gastric lymphoma were 86% and 84% respectively with no statistical difference (p=0.5).
  • Because of the indolent course the prognosis of MALT lymphoma was good regardless of the treatment modalities.
  • The treatment choice should be patient-tailored, taking into account the site, stage, age and other clinical characteristic of patient.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27263619.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


8. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol; 2005 Oct;16(10):1675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK).
  • PATIENTS AND METHODS: Three hundred and six patients with follicular or mantle cell lymphoma received four weekly doses of rituximab (induction) and no further treatment (arm A) or four more doses at 2-month intervals (arm B).
  • Factors associated with event-free survival (EFS) were having responded to induction, having received not more than one line of therapy, Ann Arbor stage I-III, high lymphocyte count, disease bulk <5 cm, Fc-gamma receptor genotype VV and receiving prolonged treatment.
  • Prolonged treatment results in longer EFS at the cost of a longer reduction in B cell and IgM levels, but without additional clinical toxicity.


9. Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS: Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma; 2010 Jul;51(7):1217-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience.
  • The purpose of this study was to assess the clinicopathologic characteristics and outcomes in patients with diffuse large B-cell lymphoma (DLBCL) of the testis, and to assess the impact of changes in the therapeutic approach that have occurred over the years.
  • Factors analyzed included: age, clinical stage, B-symptoms, serum levels of lactate dehydrogenase (LDH), beta(2)-microglobulin, treatment received, and outcome.
  • Immunophenotypic data were available for 43 cases, all of which showed B-cell lineage.
  • On univariate analysis, stages III and IV (p = 0.042), elevated serum LDH (p = 0.014), B-symptoms (p = 0.003), and high-intermediate or high International Prognostic Index (IPI) score (p = 0.010) were associated with a significantly decreased overall survival (OS) and progression-free survival (PFS).
  • Advanced stage, elevated serum LDH, B-symptoms, and high IPI are poor prognostic markers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Jul;51(7):1159-60 [20497004.001]
  • (PMID = 20443676.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / beta 2-Microglobulin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone
  •  go-up   go-down


10. d'Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M, Bang B, Hagberg H: Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol; 2010 Sep;150(5):565-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
  • The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated.
  • Twenty-one adult patients with relapsed or refractory CD4(+) PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks.
  • Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629661.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / zanolimumab
  •  go-up   go-down


11. Lin H, Sun XF, Zhen ZJ, Xia Y, Xiang XJ, Ling JY, Liu DG, Xia ZJ, Huang HQ, Luo WB, Zheng L, Lin TY, Guan ZZ: [Clinical analysis of 69 cases of Burkitt's lymphoma]. Ai Zheng; 2008 Apr;27(4):425-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 69 cases of Burkitt's lymphoma].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is a kind of highly aggressive B-cell lymphoma.
  • There is no large-scale report concerning Burkitt's lymphoma in China yet.
  • This study was to summarize the characteristics of Burkitt's lymphoma in China.
  • METHODS: Clinical data of 69 Burkitt's lymphoma patients, treated from May 1985 to May 2007 in Cancer Center of Sun Yat-sen University, were analyzed.
  • RESULTS: Of the 69 patients, 44 were men and 25 were women, with a median age of 7 (range, 2-72); 5 were at stage I, 9 at stage II, 21 at stage III, and 34 at stage IV, advanced stage (stages III and IV) accounted for 55 (79.7%) patients.
  • CONCLUSION: The clinical characteristics of these 69 Burkitt's lymphoma patients are much similar to those from sporadic areas, but the median age is lower, and the most common involved sites are cervical lymph nodes, abdomen and faciomaxillary-oropharynx.
  • [MeSH-major] Burkitt Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423131.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


12. Li YL, Liu WP, Tang Y, Zhao S, Zuo Z, Yang YH, Yang QP, Luo TY: [Small cell variant of peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic and immunophenotypic analysis]. Zhonghua Bing Li Xue Za Zhi; 2009 May;38(5):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell variant of peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic and immunophenotypic analysis].
  • OBJECTIVE: To study the clinicopathologic features and differential diagnosis of small cell variant of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS).
  • METHODS: The clinicopathologic features of 5 cases of small cell variant of PTCL, NOS were retrospectively reviewed, with immunohistochemical study, T-cell receptor (TCR) gene rearrangement analysis and evaluation for Epstein-Barr virus (EBV) status.
  • Clinically, 3 patients presented in stage IV and 2 in stage III.
  • Immunohistochemically, the lymphoma cells in all cases expressed two or more of the T-cell markers and CD43.
  • CONCLUSION: Small cell variant of PTCL, NOS represents a rare disease entity which often presents in advanced tumor stage and carries a poor prognosis.
  • [MeSH-major] Antigens, CD3 / metabolism. Antigens, CD43 / metabolism. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Lymphoma, T-Cell, Peripheral / metabolism. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Immunophenotyping. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575875.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD43; 0 / CD3E protein, human; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; COP protocol 2
  •  go-up   go-down


13. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol; 2005 Mar 20;23(9):1984-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
  • PURPOSE: Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years.
  • In an attempt to improve outcome, the German Low Grade Lymphoma Study Group (GLSG) initiated a randomized trial comparing the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and rituximab (R-CHOP) with CHOP alone as first-line therapy for advanced-stage MCL.
  • PATIENTS AND METHODS: One hundred twenty-two previously untreated patients with advanced-stage MCL were randomly assigned to six cycles of CHOP (n = 60) or R-CHOP (n = 62).
  • Patients up to 65 years of age achieving a partial or complete remission underwent a second randomization to either myeloablative radiochemotherapy followed by autologous stem-cell transplantation or interferon alfa maintenance (IFNalpha).
  • Hence, R-CHOP may serve as a new baseline regimen for advanced stage MCL, but needs to be further improved by novel strategies in remission.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Interferon-alpha / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Female. Germany. Humans. Male. Middle Aged. Rituximab. Stem Cell Transplantation. Treatment Failure

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6802; author reply 6802-3 [16170194.001]
  • (PMID = 15668467.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Interferon-alpha; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. Kelsey CR, Beaven AW, Diehl LF, Prosnitz LR: Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant? Oncology (Williston Park); 2010 Nov 30;24(13):1204-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?
  • Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the United States.
  • The role of RT in advanced-stage DLBCL has not been firmly established, but some prospective phase III trials, as well as retrospective studies, suggest a benefit for advanced disease also.
  • For patients with relapsed or primary refractory disease, autologous stem cell transplantation is the treatment of choice.
  • Here too, consolidation RT appears to improve outcomes compared with autologous stem cell transplant alone.
  • Finally, for patients with advanced DLBCL who are no longer responsive to systemic therapy, RT may provide rapid and durable palliation of local lymphoma-related symptoms.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / radiotherapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Nov 30;24(13):1213-4 [21192560.001]
  • (PMID = 21192559.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T: Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma; 2006 Oct;47(10):2140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG).
  • The aim of this retrospective study was to illustrate the clinicopathologic data and the treatment results in patients with primary gastrointestinal tract non-Hodgkin's lymphoma (GI NHL).
  • Overall, 67.2% of the patients were in stages I - II, and 32.8% in stages III - IV.
  • Extranodal marginal zone B-cell lymphoma (MZBL) (i.e., low-grade lymphoma of mucosa-associated lymphoid tissue type) accounted for 48.4% of lymphomas.
  • Aggressive lymphomas (diffuse large B-cell lymphoma [DLBL]) accounted for 44.5%.
  • The major prognostic factor for outcome in the present study was the stage of the disease.
  • Patients with localized lymphoma (stage I and II) had significantly longer DFS and OS (DFS and OS at 3-year: 83% and 87%, respectively) than patients with extended disease (stage III and IV) (DFS and OS at 3-year: 46% and 60%, respectively) (P < 0.0001).
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071488.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Chen DG, Yang Y, Pan CZ: [Primary mediastinal large B-cell lymphoma:a report of 24 cases with literature review]. Ai Zheng; 2008 Feb;27(2):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mediastinal large B-cell lymphoma:a report of 24 cases with literature review].
  • BACKGROUND & OBJECTIVE: Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon subtybe of diffuse large B-cell lymphoma (DLBCL).
  • RESULTS: Of the 24 patients, 16 were men and 8 were women, aged from 12 to 81; 20 were at stage I-II, 1 at stage III, and 3 at stage IV; 13 had bulk disease; 10 had superior vena cava syndrome; 14 had contiguous infiltration; 15 had lacate dehydrogenase elevation; 11 received chemoradiotherapy, 10 received chemotherapy alone, and 3 received radiotherapy alone; 10 achieved complete remission (CR) after scheduled treatment, 12 achieved partial remission (PR), 1 had stable disease and 1 had progressive disease.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy. Mediastinal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279619.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 14
  •  go-up   go-down


17. Torres HA, Kontoyiannis DP, Aguilera EA, Younes A, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF: Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin Lymphoma Myeloma; 2006 Mar;6(5):393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality.
  • BACKGROUND: Cytomegalovirus (CMV) antigenemia (CMV-A) and CMV disease (CMV-D), known causes of morbidity and mortality among patients with leukemia and recipients of hematopoietic stem cell transplantations, are described sporadically in patients with lymphoma.
  • We sought to determine the risk factors and outcome of CMV-A and CMV-D among patients with lymphoma.
  • RESULTS: Cytomegalovirus antigenemia and/or CMV-D were more common among patients with non-Hodgkin's lymphoma than among those with Hodgkin's disease (P = 0.01).
  • Most CMV infectious episodes occurred in patients who had active (88%) and stage III/IV lymphoma (84%).
  • CONCLUSION: In an era of intense and pleiotropic immunosuppressive therapy in patients with lymphoma, CMV-A and CMV-D are significant infections.
  • [MeSH-major] Cause of Death. Cytomegalovirus Infections / mortality. Immunocompromised Host. Lymphoma, Non-Hodgkin / mortality. Opportunistic Infections / mortality

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640816.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA96297
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


18. Jing HM, Ke XY, Dong F: [Analysis of prognostic correlated factors of 49 patients with mucosa-associated lymphoid tissue lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec;15(6):1293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic correlated factors of 49 patients with mucosa-associated lymphoid tissue lymphoma].
  • The aim of this study was to investigate the clinical feature of mucosa-associated lymphoid tissue lymphoma and clarify the relationship between the pathological, clinical features, the expression of API2-MALT1 and the prognosis.
  • A number of factors including pathological characters, grade, stage, prognosis and treatment of 49 cases of MALT lymphoma were analyzed, and the API2-MALT1 rearrangement was detected by RT-PCR.
  • The results showed that 49 patients were diagnosed as MALT lymphoma, in which median age was 52.4 years.
  • Among 49 patients, stage I, II was 77.
  • 6%, stage III, IV was 22.4%.
  • Among 18 patients with gastric MALT lymphoma, 9 cases (50.0%) were helicobacter pylori (HP) positive and received antibiotic treatment.
  • It is concluded that MALT lymphoma is often seen in older patients, most of them were in low grade with slow progression.
  • The site, grade, stage and molecular genetic changes are important prognostic factors, which can contribute to choosing suitable treatment for patients with MALT lymphoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088487.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


19. Ewens KG, George RA, Sharma K, Ziyadeh FN, Spielman RS: Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes; 2005 Nov;54(11):3305-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All families had at least one offspring with diabetes and end-stage renal disease or proteinuria.
  • Nevertheless, nominally significant TDT results (P < 0.05) were obtained with polymorphisms in 20 genes, including 12 that have not been studied previously: aquaporin 1; B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene; catalase; glutathione peroxidase 1; IGF1; laminin alpha 4; laminin, gamma 1; SMAD, mothers against DPP homolog 3; transforming growth factor, beta receptor II; transforming growth factor, beta receptor III; tissue inhibitor of metalloproteinase 3; and upstream transcription factor 1.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249459.001).
  • [ISSN] 0012-1797
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-55227
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


20. Yun J, Kim SJ, Won JH, Choi CW, Eom HS, Kim JS, Kim MK, Kwak JY, Kim WS, Suh C: Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. Leuk Res; 2010 Sep;34(9):1175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report.
  • Fourteen patients had primary ovarian lymphoma, while eighteen patients had secondary ovarian involvement.
  • There was no significant difference in survival rates between primary and secondary involvement with diffuse large B-cell lymphoma (DLBCL), the most common subtype.
  • The localized bilateral ovarian involvement showed poorer survival compared to stage III/IV patients with secondary ovarian involvement.
  • Treatment outcomes of secondary ovarian involvement in non-Hodgkin's lymphoma were comparable to those of primary ovarian involvement, suggesting that ovarian involvement does not necessarily predict a worse prognosis for NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206997.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW Jr, Dien PY, Lyons R, Schlegel PJ, Vukelja SJ, Boston J, Boehm KA, Wang Y, Asmar L: Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood; 2010 Jan 21;115(3):475-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
  • This study evaluated the efficacy and safety of single-agent bortezomib in indolent B-cell lymphoma that had relapsed from or was refractory to rituximab.
  • The median age was 70 years, 53% female, Ann Arbor stage III-IIIE (28%) and IV (65%); 43 patients (72%) had more than 2 prior regimens; and 6 patients went on to maintenance.
  • This study demonstrates that bortezomib has modest activity against marginal zone and follicular lymphoma; it has the potential for combination with other agents in low-grade lymphomas.
  • [MeSH-major] Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Pyrazines / therapeutic use

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965689.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


22. Schneider T, Molnár Z, Deák B, Várady E, Tóth E, Csomor J, Matolcsy A, Lovey J, Lengyel Z, Petri K, Gaudi I, Rosta A: [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma]. Orv Hetil; 2009 Nov 1;150(44):2019-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
  • [Transliterated title] Diffúz nagy B-sejtes lymphomák immunokemoterápiás kezelésével elért eredményeink.
  • Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years.
  • The eligibility criteria included advanced stage (clinical stages III-IV), or large tumour size (>7 cm) and/or symptom B or extranodal manifestation in the case of clinical stages I-II.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / immunology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861288.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


23. Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon PA, Thieblemont C, Coiffier B, Salles G, Berger F: A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology; 2006 Jan;48(2):162-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases.
  • AIMS: To report the clinicopathological findings of 21 cases of primary nodal marginal zone B-cell lymphoma (NMZL).
  • NMZL is a recently characterized lymphoma and few series have been published.
  • METHODS AND RESULTS: The clinical data were characteristic of a disseminated disease at presentation: presence of peripheral and abdominal lymph nodes, bone marrow involvement (62%), disease stage III and IV (76%), elevated lactate dehydrogenase (LDH) (48%).
  • Morphological features were heterogeneous and there were some differences compared with other marginal zone B-cell lymphomas (MZL).
  • Pure monocytoid B-cell lymphomas were rare (10%) but a minor component of monocytoid B cell was observed more frequently (23%).
  • [MeSH-major] Lymphoma, B-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405665.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


24. Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF: A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother; 2010 Feb-Mar;33(2):178-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
  • We evaluated the efficacy and safety of patient-specific immunotherapy with mitumprotimut-T idiotype keyhole limpet hemocyanin and granulocyte-monocyte colony-stimulating factor (GM-CSF) following rituximab in patients with follicular B-cell lymphoma.
  • Patients with previously untreated or relapsed/refractory CD20+ follicular lymphoma received 4 weekly infusions of rituximab and those with a complete response (CR), partial response (PR), or stable disease received mitumprotimut-T and GM-CSF injections subcutaneously.
  • Among 103 patients treated with rituximab, 92 (54 relapsed/refractory and 38 previously untreated) received mitumprotimut-T/GM-CSF; median age was 53 years, 91% had stage III to IV disease, and 59% had failed earlier therapy.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Immunotherapy. Lymphoma, B-Cell / therapy. Lymphoma, Follicular / therapy. Recombinant Fusion Proteins / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145546.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Immunoglobulin Idiotypes; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin
  •  go-up   go-down


25. Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M: A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma; 2009 May;50(5):716-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
  • Salvage therapy for patients with mantle cell lymphoma (MCL) remains a challenge.
  • On the basis of studies demonstrating synergy in vitro, eight heavily pretreated patients (median age 65 years) with advanced stage MCL were individually treated with a novel combination protocol consisting of the proteasome inhibitor bortezomib (1.5 mg/m(2); Days 1 and 4), high-dose cytarabine (750-2000 mg/m(2); Days 2 and 3) and dexamethasone (40 mg daily; Days 1-4).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / administration & dosage. Cytarabine / administration & dosage. Lymphoma, Mantle-Cell / drug therapy. Pyrazines / administration & dosage. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347767.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib
  •  go-up   go-down


26. Cvetković RS, Perry CM: Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. BioDrugs; 2006;20(4):253-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
  • In phase III trials in patients with indolent or aggressive B-cell non-Hodgkin lymphoma (NHL), intravenous rituximab in combination with chemotherapy was more effective as first- or second-line therapy than chemotherapy alone in terms of tumor remission and patient survival.
  • In addition, rituximab maintenance therapy was shown to significantly prolong tumor remission and patient survival in patients with indolent B-cell NHL or CLL.
  • The combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was cost effective as first-line therapy for advanced-stage diffuse large B-cell NHL compared with CHOP alone.
  • Overall, rituximab in combination with chemotherapy, is a valuable option for first- and second-line therapy in patients with advanced-stage indolent or aggressive B-cell NHL, and possibly those with B-cell CLL, and is included in current treatment guidelines for these indications.
  • The drug is also potentially useful as maintenance therapy in patients with indolent B-cell NHL or CLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy


27. Nakashima Y, Shiratsuchi M, Abe Y, Muta K, Tani K, Shiokawa S, Nishimura J: Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma. Leuk Lymphoma; 2005 Aug;46(8):1217-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma.
  • To achieve a sustained complete remission, we performed planned non-myeloablative allogeneic stem cell transplantation (NST) after autologous hematopoietic stem cell transplantation (HSCT) in a patient with stage III MM.
  • [MeSH-major] Graft vs Tumor Effect / immunology. Hematopoietic Stem Cell Transplantation / methods. Multiple Myeloma / therapy


28. Gopal AK, Metcalfe TL, Gooley TA, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Maloney DG, Press OW: High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer; 2008 Sep 15;113(6):1344-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
  • BACKGROUND: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), but this therapy is commonly denied to patients with resistant disease.
  • Baseline characteristics included median age = 35 years (range, 14-59 years), stage III/IV = 49 (77%), nodular sclerosis histology = 51 (80%), and prior radiation = 32 (50%).
  • Twenty-six patients (41%) received total body irradiation (TBI)-based regimens, and 38 (59%) underwent non-TBI conditioning.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:67-71 [2049322.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):139-43 [6174060.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):704-11 [8478664.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1381-90 [7858268.001]
  • [Cites] Nouv Rev Fr Hematol. 1994 Dec;36(6):423-30 [7753613.001]
  • [Cites] Blood. 1997 Feb 1;89(3):801-13 [9028311.001]
  • [Cites] Blood. 1997 Feb 1;89(3):814-22 [9028312.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(9):745-52 [9384476.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):289-95 [9602263.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):461-7 [15534357.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):625-33 [15737986.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):943-51 [15806128.001]
  • [Cites] Lancet. 2005 Jun 4-10;365(9475):1934-41 [15936420.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4669-78 [16034043.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2896-902 [16002426.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83 [16443515.001]
  • [Cites] Blood. 2006 Jul 15;108(2):705-10 [16551968.001]
  • [Cites] Bone Marrow Transplant. 2006 Aug;38(3):211-6 [16770314.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1071-9 [17426059.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1485-8 [10643540.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):665-72 [10942053.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1395-404 [11230484.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2351-7 [12750161.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 4):54-9 [15124135.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1222-30 [15277262.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):210-8 [1732422.001]
  • (PMID = 18623377.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA044991-21; United States / NCI NIH HHS / CA / K08 CA095448; United States / NCI NIH HHS / CA / CA095448-05; United States / NCI NIH HHS / CA / K08 CA095448-05; United States / NCI NIH HHS / CA / K23 CA085479; United States / NCI NIH HHS / CA / P01 CA044991; United States / NCI NIH HHS / CA / K23CA85479; United States / NCI NIH HHS / CA / K23 CA085479-06; United States / NCI NIH HHS / CA / P01CA44991; United States / NCI NIH HHS / CA / K08CA095448; United States / NCI NIH HHS / CA / CA085479-06; United States / NCI NIH HHS / CA / CA044991-21
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS115907; NLM/ PMC2700660
  •  go-up   go-down


29. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer; 2008 Aug 15;113(4):791-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
  • BACKGROUND: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin's lymphoma.
  • RESULTS: Of the 87,166 patients diagnosed with non-Hodgkin's lymphoma during the 13-year period between 1992 and 2004, 2459 (2.8%) had confirmed MCL.
  • Late-stage (III-IV) MCL was diagnosed in 74.6% of patients.
  • Most patients were diagnosed with late-stage MCL, and there also were considerable geographic variations observed in incidence rate.
  • [MeSH-major] Lymphoma, Mantle-Cell / epidemiology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 American Cancer Society
  • (PMID = 18615506.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R01-HS016743
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


30. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • Forty-one patients underwent involved-field radiotherapy in conjunction with high-dose chemotherapy and bone marrow or peripheral stem cell transplantation.
  • Thirty-three patients received involved-field radiotherapy prior to stem cell transplantation directed at symptomatic and/or bulky sites; eight patients received involved-field radiotherapy after stem cell transplantation directed at sites of persistent disease.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • Data were analyzed using Cox proportional hazards regression to determine the risk of death among patients treated with stem cell transplantation compared with that among patients treated with stem cell transplantation and involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • When patients were treated with involved-field radiotherapy prior to stem cell transplantation, 27 (79.4%) of the 34 patients achieved local control; when involved-field radiotherapy followed stem cell transplantation, 6 (85.7%) of the 7 patients experienced local control.
  • Timing of involved-field radiotherapy prior to or following stem cell transplantation did not affect patient survival.
  • CONCLUSIONS: Although of borderline significance in this small sample, results of this study suggest that patients who receive involved-field radiotherapy in conjunction with stem cell transplantation may have increased survival when compared with patients who do not receive involved-field radiotherapy.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Kim SJ, Lee SJ, Sung HJ, Choi IK, Choi CW, Kim BS, Kim JS, Yu W, Hwang HS, Kim IS: Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol; 2008;120(4):211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas.
  • The role of 90K and galectin-3 in cell-to-extracellular matrix adhesion and tumor metastasis has been reported, but little is known about their role in the prognosis and extranodal involvement of diffuse large B-cell lymphomas (DLBCL).
  • High serum 90K (median value >or=1,249.50 ng/ml) and high galectin-3 expression (grade 3 positive staining in >75% of cells) showed a significant association with stage III/IV, >or=2 extranodal involvements and risk of high/high-intermediate international prognostic index (p < 0.05).
  • In conclusion, serum 90K and galectin-3 expression might be useful markers to indicate the extent of lymphoma involvement and prognosis in DLBCL.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor. Galectin 3 / biosynthesis. Lymphoma, Large B-Cell, Diffuse / blood. Lymphoma, Large B-Cell, Diffuse / pathology. Membrane Glycoproteins / blood

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153476.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Membrane Glycoproteins; 0 / TAA90K protein, human
  •  go-up   go-down


32. Feng LJ, Zhang GP, Xie M, Cao PF, Fu CY, Hu ZL, Dai M: [Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jul;11(7):555-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma].
  • OBJECTIVE: Some research has shown that primary intestinal lymphoma with the same immunophenotype has different prognosis.
  • This study aimed to explore the role of the p53 gene and chromosome 13q14 variations in the assessment of prognosis in primary intestinal lymphoma.
  • METHODS: p53 gene and chromosome 13q14 expression in paraffin sections of 30 cases of primary intestinal lymphoma and 10 cases of lymph node reactive hyperplasia were ascertained using an improved FISH technique.
  • RESULTS: p53 gene deletion was found in 22.7% of patients with primary intestinal lymphoma at stage I-II and in 75.0% of patients at stage III-IV (x2=6.903, p<0.01).
  • The 30 patients with primary intestinal lymphoma were pathologically classified into-mucosa-associated lymphoid tissue (MALT) (n=14) and non-MALT types (n=16).
  • The MALT lymphoma group had significantly lower incidence of p53 gene deletion (14.3% vs 56.3%; x2=5.662, p<0.05).
  • 13q14 deletion was found in 40.0% of patients with primary intestinal lymphoma, but none of patients with lymph node reactive hyperplasia showed 13q14 deletion.
  • 13q14 deletion was not significantly related to the pathological type and the clinical stage of primary intestinal lymphoma as well as the survival time.
  • CONCLUSIONS: There was a high incidence of p53 gene deletion in patients with non-MALT lymphoma or at stage III-IV. p53 gene deletion is related to a high tumor malignant degree and a poor prognosis, while-chromosome 13q14 variation is not associated with the prognosis in patients with primary intestinal lymphoma.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 13. Genes, p53. Intestinal Neoplasms / genetics. Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Humans. In Situ Hybridization, Fluorescence. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / mortality. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650989.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ: [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
  • OBJECTIVE: The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin's lymphoma (NHL).
  • RESULTS: Of these 121 patients, 83 (68.6%) had B-cell NHL and 38(31.4%) peripheral T or NK-cell NHL; 55.
  • 4% (67/121) had early disease (stage I or II), and 89.3% (108/121) had IPI score 0-2.
  • Major toxicity consisted of grade III-IV myelosuppression (11.9%), neutropenia (1.9%) and thrombocytopenia and anemia (1.1%).
  • CONCLUSION: Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Child. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Analysis. Thrombocytopenia / chemically induced. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892140.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


34. Koumarianou AA, Xiros N, Papageorgiou E, Pectasides D, Economopoulos T: Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades. Anticancer Res; 2007 Mar-Apr;27(2):1191-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
  • The prognostic factors, treatments and outcomes of 55 young adults (16-23 years old) with Hodgkin lymphoma (HL) treated in the Second Department of Internal Medicine Propaedeutic, Medical Oncology Unit, Athens University, over the past 25 years, are reviewed.
  • Additionally, the patients were retrospectively divided according to risk factors (abnormal erythrocyte sedimentation rate (ESR), bulky mediastinal disease, > 3 involved nodes and extranodal involvement) into low [stage I/II; five patients (9%)], intermediate [stage III with adverse prognostic factors; 18 patients (33%)] and high risk categories [stages IIB bulky and III/IV; 32 patients (58%)].
  • Current controversial issues surrounding this disease, including the role of radiotherapy, positron emission tomography (PET), bone marrow biopsy and stem cell transplantation are discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy


35. Byrne BJ, Gockerman JP: Salvage therapy in Hodgkin's lymphoma. Oncologist; 2007 Feb;12(2):156-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy in Hodgkin's lymphoma.
  • Hodgkin's disease is a rare malignancy that affects approximately 7,500 patients per year in the U.S., leading to an estimated 1,400 deaths.
  • The relapse rate for this disease varies from around 5% for early-stage disease to 35% for patients with advanced disease.
  • Two randomized phase III studies have shown an improved failure-free survival rate with high-dose chemotherapy and autologous stem cell support compared with conventional chemotherapy in relapsed patients.
  • Further studies on the use of monoclonal antibodies and radiolabeled antibodies need to be conducted to define their role in the treatment of Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / therapy. Salvage Therapy
  • [MeSH-minor] Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296811.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


36. Nicotra G, Manfroi F, Follo C, Castino R, Fusco N, Peracchio C, Kerim S, Valente G, Isidoro C: High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome. Dis Markers; 2010;28(3):167-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome.
  • We investigated whether the level of CD expression influences the progression and the clinical outcome in Non-Hodgkin's Lymphomas (NHLs).
  • The expression of CD was assessed by immunohistochemistry and immunofluorescence in biopsies of Diffuse Large B Cell Lymphomas (DLBCL, 35 cases), Follicular Lymphomas (FL, 9 cases of grade I-II plus 14 cases of grade IIIB), Chronic Lymphocytic Leukaemias (CLL, 17 cases) and Peripheral T-cell Lymphomas (PTCL, 5 cases).
  • Lymphomas highly expressing CD were associated with a worse stage (III-IV) at diagnosis (31/34 cases; p=0.002) and with a poor clinical outcome (i.e., partial remission and death; 28/34 cases; p=0.03).
  • In Cox multivariate analysis CD failed to be a prognosticator independent of pathologic stage, though the hazard ratio confirmed the association of low expression with a better survival probability.
  • [MeSH-major] Cathepsin D / metabolism. Lymphoma, Non-Hodgkin / enzymology

  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534902.001).
  • [ISSN] 1875-8630
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.23.5 / Cathepsin D
  • [Other-IDs] NLM/ PMC3833244
  •  go-up   go-down


37. Kobayashi R, Yamato K, Tanaka F, Takashima Y, Inada H, Kikuchi A, Kumagai MA, Sunami S, Nakagawa A, Fukano R, Fujita N, Mitsui T, Tsurusawa M, Mori T, Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group: Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer; 2010 Feb;54(2):212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan.
  • BACKGROUND: Reports of non-anaplastic peripheral T-cell lymphoma (PTCL) in pediatric patients are relatively rare.
  • RESULTS: We could analyze clinical data in 21 patients with non-anaplastic PTCL; 10 were female and 10 male.
  • There were nine patients with PTCL, not otherwise specified (PTCL-NOS); ten with extranodal NK/T-cell lymphoma, nasal type; one with angioimmunoblastic T-cell lymphoma; and one with subcutaneous panniculitis-like T-cell lymphoma.
  • There were 12 patients with advanced stage disease (stages III and IV).
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / epidemiology. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Japan / epidemiology. Male. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19856396.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Ozdogu H, Boga C, Kizilkilic E, Kozanoglu I, Karakus S, Sahin FI, Unalan D, Haberal M: The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center. Transplant Proc; 2007 May;39(4):1257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
  • Autologous stem cell transplantation is the current standard approach for patients with multiple myeloma and relapsed or refractory lymphoma.
  • Nonmyeloablative allogeneic stem cell transplantation has been applied worldwide.
  • Seven evaluable patients younger than 65 years old with stage II/III multiple myeloma were treated with high-dose melphalan therapy (140 mg/m(2)) plus autologous peripheral blood stem cell transplantation.
  • Four patients with acute myeloblastic leukemia underwent nonmyeloablative allogeneic peripheral stem cell transplantation.
  • All other patients in remission remained with >90% donor cell engraftment.
  • [MeSH-major] Hematologic Neoplasms / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods. Transplantation, Autologous
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Communicable Disease Control. Cyclosporine / therapeutic use. Female. Hematopoietic Stem Cell Mobilization. Humans. Immunosuppressive Agents / therapeutic use. Male. Melphalan / therapeutic use. Middle Aged. Mitoxantrone / therapeutic use. Patient Selection. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524948.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


39. Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD, Cancer and Leukemia Group B Study 9153: Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer; 2006 Dec 15;107(12):2817-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
  • BACKGROUND: The objective of this study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in patients with untreated, indolent non-Hodgkin lymphoma (NHL).
  • METHODS: For this multicenter, single-arm, Phase II study, 44 patients with treatment-naive, stage III or IV, indolent NHL (International Working Formulation subtypes A, B, and C) were enrolled.
  • Four late malignancies (prostate adenocarcinoma, ductal carcinoma in situ, and myelodysplasia) and 4 patients with large cell transformation were reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cladribine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17120198.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47555; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


40. Krejci M, Scudla V, Tothova E, Schutzova M, Koza V, Adam Z, Krivanova A, Pour L, Buchler T, Sandecka V, Kralova D, Zahradova L, Vorlicek J, Mayer J, Hajek R: Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. Clin Lymphoma Myeloma; 2009 Dec;9(6):436-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Autologous stem cell transplantation (autoSCT) has an important role in the treatment of patients with symptomatic multiple myeloma (MM).
  • On multivariate analysis, factors associated with significantly better OS were International Staging System (ISS) disease stage < III (hazard ratio [HR], 2.6; P < .001), achievement of CR after autoSCT (HR, 2.8; P < .001) and use of thalidomide (HR, 4.3; P < .001) and/or bortezomib (HR, 7.3; P < .001) in posttransplantation relapse treatment.
  • CONCLUSION: According to our results, the achievement of CR after transplantation, ISS stage other than III, and administration of thalidomide or bortezomib in posttransplantation relapse were significant parameters favoring long-term posttransplantation survival.
  • [MeSH-major] Boronic Acids / therapeutic use. Hematopoietic Stem Cell Transplantation. Multiple Myeloma / therapy. Pyrazines / therapeutic use. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951883.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib
  •  go-up   go-down


41. Chen CQ, Yin L, Peng CH, Zhao R, Chen GM, Zhou HJ, Li HW: [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases].
  • OBJECTIVE: To study the clinical characteristics,treatment and prognosis of primary non-Hodgkin's lymphoma of small bowel.
  • METHODS: The records of 34 patients with a confirmed diagnosis of primary non-Hodgkin's lymphoma of small bowel, registered between Jan.
  • RESULTS: Twenty-seven patients had B-cell lymphoma and 7 had T-cell lymphoma of the small bowel.
  • According to Ann Arbor staging classification, 22 patients belonged to stage I~II, including 20 cases of B-cell lymphoma and 2 cases of T-cell lymphoma, and 12 patients belonged to stage III~IV, including 7 cases of B-cell lymphoma and 5 cases of T-cell lymphoma.
  • Compared with T-cell lymphoma patients, B-cell lymphoma patients had lower lymphoma stages (P<0.05).
  • T-cell lymphoma patients were more often treated with emergent operation than B-cell lymphoma patients would (P<0.05).
  • It happened more frequently that B-cell lymphoma patients reached complete remission and their accumulative survival rate was longer than T-cell lymphoma patients did (P<0.05).
  • CONCLUSION: Patients with stages I and II B-cell lymphoma of small bowel respond well to surgery and chemotherapy, and the treatment and prognosis of patients with T-cell lymphoma of small bowel are unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies


42. Salem HA, Eissa LA, Rabbie AM, El-Helw LM, El-Gayar AM: Evaluation of some biochemical markers as prognostic factors in malignant lymphomas. Pak J Pharm Sci; 2006 Jul;19(3):219-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage.
  • For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin's disease (HD) and 31 with Non-Hodgkin's lymphoma (NHL) were selected from Mansoura University Hospital.
  • Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV.
  • 3- Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • [MeSH-major] Biomarkers, Tumor. Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Blood Cell Count. Blood Sedimentation. Female. Glycosaminoglycans / metabolism. Humans. Kidney Function Tests. L-Lactate Dehydrogenase / metabolism. L-Selectin / metabolism. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Tumor Necrosis Factor, Type I / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935830.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycosaminoglycans; 0 / Receptors, Tumor Necrosis Factor, Type I; 126880-86-2 / L-Selectin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


43. Tang YJ, Tang JY, Pan C, Xue HL, Chen J, Shen SH, Dong L, Zhou M, Wang YP, Gu LJ, Jiang H, Ye QD: [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children]. Zhonghua Er Ke Za Zhi; 2009 Sep;47(9):687-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children].
  • OBJECTIVE: Non-Hodgkin's lymphoma (NHL) presenting as mediastinal mass is usually progressive and may cause severe respiratory distress and death.
  • For staging, the St. Jude system was applied.
  • Of them, 24 were lymphoblastic lymphoma and 3 were anaplastic large cell lymphoma.
  • All the 36 cases were T-cell type.
  • Twenty-four cases were in stage III, 12 in stage IV.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Mediastinal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021793.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


44. Lloret M, Lara PC, Bordón E, Fontes F, Rey A, Pinar B, Falcón O: Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):976-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty patients had Stage I disease, 45 had Stage II, and 31 had Stage III/IVA.
  • Most patients had squamous tumors (98 cases) and Grades II (52 cases) and III (45 cases) carcinomas.
  • Expression of MVP, Ku70/80, Insulin-Like Growth Factor-1 receptor (IGF-1R), BCL2-associated X protein (BAX), B-cell CLL/lymphoma 2 (BCL-2), p53, and Ki67 was studied by using immunohistochemistry in paraffin-embedded tumor tissue.
  • These mechanisms may be associated with the decision of damaged cells to survive and proliferate, favoring tumor progression and reducing tumor response to oncologic treatment through the development of resistant cell phenotypes.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Chromosomal Instability / genetics. DNA Damage / genetics. Down-Regulation. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies. Receptor, IGF Type 1 / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251084.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 0 / Vault Ribonucleoprotein Particles; 0 / bcl-2-Associated X Protein; 0 / major vault protein; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


45. Lenz G, Dreyling M: Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL? Nat Clin Pract Oncol; 2005 Feb;2(2):72-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Rituximab. Stem Cell Transplantation. Thalidomide / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264875.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


46. Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC: Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol; 2006 Oct;17(10):1546-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).
  • INTRODUCTION: Sequential high dose (SHiDo) chemotherapy with stem cell support has been shown to prolong the event-free survival in patients with diffuse large B-cell lymphoma.
  • RESULTS: 129 evaluable patients were randomized to receive either CHOP or SHiDo: median age, 48 years; 62% male; stage III+IV: 73%; age adjusted International Prognostic Index 1/2/3: 21%/52%/27%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Neoadjuvant Therapy / methods


47. Di Bella N, Reynolds C, Faragher D, Muscato J, Boehm KA, Asmar L: An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma. Cancer; 2005 Mar 1;103(5):978-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.
  • BACKGROUND: In a previous study, the authors demonstrated that the combination of pentostatin (P) and rituximab (R) was well tolerated and was active in patients with low-grade non-Hodgkin lymphoma (NHL).
  • METHODS: Twenty-four previously untreated patients with histologically proven, Stage III or IV, low-grade NHL were registered between April and September, 2002.
  • Eighty-three percent of patients had Stage IV disease, the median patient age was 62 years (range, 4-81 years), and the performance status was 0-2.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin. Male. Middle Aged. Mitoxantrone / administration & dosage. Pentostatin / administration & dosage. Pilot Projects. Rituximab. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15672388.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


48. Avilés A, Cleto S, Castañeda C, Nambo MJ: CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology; 2007 Jun;12(3):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CMED in the treatment of nasal natural killer cell lymphoma with distant metastases.
  • INTRODUCTION: Nasal natural killer (NK) cell lymphoma that showed distant metastases generally showed an poor prognosis.
  • METHODS: Sixty-one patients fulfilled the criteria for NK cell lymphoma with distant metastases and all have very poor prognostic factors: high clinical risk, multiple extranodal presentation and bulky disease (tumor mass >10 cm).
  • CONCLUSIONS: Nasal NK cell lymphoma with distant metastases is considered an rare clinical entity, probably is under diagnosis because it has been included as stage III and IV in previous reports, that showed an very poor RFS and OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Killer Cells, Natural. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Metastasis. Nose Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558700.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


49. Dreyling M, Hiddemann W, European MCL Network: Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program; 2009;:542-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment standards and emerging strategies in mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas characterized by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression in the vast majority of cases.
  • Most patients present with advanced stage disease, often with extranodal dissemination, and pursue an aggressive clinical course in the majority of cases.
  • Recent improvement has been achieved by the successful introduction of monoclonal antibodies and dose-intensified approaches including autologous stem cell transplantation (ASCT) strategies.
  • With the exception of allogeneic hematopoietic stem cell transplantation, current treatment approaches are non-curative and the corresponding survival curves are characterized by a delayed, but continuous decline and a median survival of 4 to 6 years.
  • Emerging strategies such as proteasome inhibitors, IMIDs, mTOR inhibitors and others are based on the dysregulated control of cell cycle machinery and impaired apoptotic pathways.


50. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol; 2009 Feb 1;27(4):511-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of overall survival in advanced stage mantle cell lymphoma.
  • PURPOSE: Mantle cell lymphomas (MCLs) represent a clinically aggressive lymphoma subtype with a poor prognosis.
  • To explore a potential progress in outcome a historical comparison was performed using data from the Kiel Lymphoma Study Group (KLSG; 1975 to 1986) and the German Low Grade Lymphoma Study Group (GLSG; 1996 to 2004).
  • PATIENTS AND METHODS: All patients with the histologically confirmed diagnosis of advanced-stage nonblastoid MCL were eligible.
  • Potential reasons for this apparent improvement in overall survival include the application of anthracycline-containing regimens and new approaches, such as antilymphoma antibodies or stem cell transplantation.
  • [MeSH-major] Lymphoma, Mantle-Cell / mortality

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Feb 1;27(4):481-3 [19075257.001]
  • (PMID = 19075279.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


51. Zhai LZ, Xiao J, Fu XH, Ye S, Guo CC, Huang JJ, Tian Y, Lin HL, Lin TY: [Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma: a report of 90 cases]. Ai Zheng; 2009 Jul;28(7):734-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma: a report of 90 cases].
  • BACKGROUND AND OBJECTIVE: Mucosa-associated lymphoid tissue lymphoma is a histological type of marginal zone non-Hodgkin's lymphoma (NHL).
  • METHODS: Clinical data of 90 pathologically confirmed mucosa-associated lymphoid tissue lymphoma patients, treated from December 1997 to February 2007, were analyzed.
  • RESULTS: Of the 90 patients, 23 (25.6%) had gastric lymphoma and 67 (74.4%) had non-gastric lymphoma, with a median age of 52 (range, 13-77); 75 (83.3%) had stage I-II disease and 15 (16.7%) had stage III-IV disease; 31 (34.4%) had multiple organ involvement and 40 (44.4%) had nodal involvement.
  • The percentage of nodal involvement was significantly higher in non-gastric group than in gastric group (P=0.040).
  • In non-gastric lymphoma group, IPI score was an independent prognostic variable of overall survival (P=0.023).
  • CONCLUSIONS: Mucosa-associated lymphoid tissue lymphoma should be considered as a kind of disseminated indolent lymphoma.
  • The patients with non-gastric lymphoma are likely to have nodal involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell, Marginal Zone. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624901.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


52. Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, Hijiya N, Campana D, Hudson MM, Ribeiro RC: Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia; 2009 Jun;23(6):1127-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
  • There has been a steady improvement in cure rates for children with advanced-stage lymphoblastic non-Hodgkin's lymphoma.
  • To further improve cure rates whereas minimizing long-term toxicity, we designed a protocol (NHL13) based on a regimen for childhood T-cell acute lymphoblastic leukemia, which features intensive intrathecal chemotherapy for central -nervous system-directed therapy and excludes prophylactic cranial irradiation.
  • From 1992 to 2002, 41 patients with advanced-stage lymphoblastic lymphoma were enrolled on the protocol.
  • Thirty patients had stage III and 11 had stage IV disease.
  • Thirty-three cases had a precursor T-cell immunophenotype, five had precursor B-cell immunophenotype and in three immunophenotype was not determined.
  • The treatment described here produces high cure rates in children with lymphoblastic lymphoma without the use of prophylactic cranial irradiation.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1340-6 [12663724.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):161-80; discussion 200-2 [12196214.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):273-9 [2355886.001]
  • [Cites] Blood. 1985 Nov;66(5):1110-4 [3840395.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):537-41 [6689428.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):630-7 [6986967.001]
  • (PMID = 19194463.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS161582; NLM/ PMC2843413
  •  go-up   go-down


53. Geskin L: ECP versus PUVA for the treatment of cutaneous T-cell lymphoma. Skin Therapy Lett; 2007 Jun;12(5):1-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
  • Extracorporeal photopheresis (ECP) and psoralen plus ultraviolet A therapy (PUVA) are widely accepted types of photochemotherapy used for the treatment of cutaneous T-cell lymphomas (CTCL).
  • ECP is usually used for patients with erythrodermic skin involvement (T4) in advanced stages (Stage III and IVA) with peripheral blood involvement as in Sézary syndrome (SzS).
  • [MeSH-major] Ficusin / therapeutic use. Lymphoma, T-Cell, Cutaneous / therapy. Photopheresis. Photosensitizing Agents / therapeutic use. Skin Neoplasms / therapy. Ultraviolet Therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PSORALEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609808.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Photosensitizing Agents; KTZ7ZCN2EX / Ficusin
  • [Number-of-references] 18
  •  go-up   go-down


54. Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ: Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma; 2007 Feb;48(2):295-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
  • To determine the impact of imatinib therapy prior to allogeneic stem-cell transplantation in advanced stage chronic myelogenous leukaemia (CML), 30 CML patients who had received imatinib as part of pre-transplant treatment were analysed, with special emphasis on the cytogenetic response to imatinib therapy shortly before transplantation.
  • In conclusion, our data suggest that advanced stage CML has an excellent outcome after allogeneic haematopoietic stem-cell transplantation when transplanted in the phase of cytogenetic response to imatinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stem Cell Transplantation


55. Xu G, Wang HF, He G, Xie K: [Expression and significance of p53-related proteins and LMP-1 in nasal NK/T-cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2009 May;31(5):351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of p53-related proteins and LMP-1 in nasal NK/T-cell lymphoma].
  • OBJECTIVE: To investigate the expression of murine double minute 2 (mdm2), p53, p21 and latent membrane protein 1 (LMP-1) in nasal NK/T-cell lymphoma (NKTL) and analyze their relationship with the clinical stage and prognosis.
  • The positive expression rates of mdm2 in Ann Arbor stage I, II, III and IV NKTL were 43.5%, 62.5%, 73.3% and 87.5%, respectively; p53 were 69.6%, 75.0%, 86.7% and 100.0%; p21 were 47.8%, 56.3%, 60.0% and 87.5%; while those of LMP-1 were 60.9%, 50.0%, 26.7% and 50.0%, respectively.
  • No statistically significant difference was observed between the expression of LMP-1 protein and the clinical stage or prognosis (P>0.05).
  • Though no significant relationship was found between the expression of LMP-1 protein and the clinical stage or prognosis, it may play some role in tumor progression.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / metabolism. Nose Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Viral Matrix Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799083.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 0 / Tumor Suppressor Protein p53; 0 / Viral Matrix Proteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


56. Jiang HY, Li HL, Hu H, He Y, Zhao T: [Detection of t (14; 18) translocation and bcl-2 amplification in diffuse large B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Feb;36(2):84-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of t (14; 18) translocation and bcl-2 amplification in diffuse large B-cell lymphoma].
  • 18) chromosomal translocation and bcl-2 amplification in classification, clinical staging and prognostic evaluation of diffuse large B cell lymphoma (DLBCL).
  • Microdissection of the lymphoma tissue was performed.
  • The phenotypes of either germinal center B-cell-like (GCB) or non-germinal center B-cell-like (non-GCB) were determined by immunohistochemistry including CD20, CD10, bcl-6 and MUM1 (S-P method) using the tissue microarray format.
  • Overall, 29 (48.3%) cases were GCB and 31 (51.7%) cases were non-GCB.
  • The t (14;. 18) was seen in 8 (80.0%) cases of GCB and 2 (20.0%) of non-GCB.
  • In these cases, the rates of complete remission, partial remission and no change were 3 (23.1%), 4 (30.8%) and 6 (46.2%) respectively, and the clinical stages were stage I - II (1 case, 7.7%) and stage III - IV (12 cases, 92.3%).
  • [MeSH-major] Gene Amplification. Genes, bcl-2. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Translocation, Genetic

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493380.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


57. Cao YB, Wang SS, Huang HQ, Xu GC, He YJ, Guan ZZ, Lin TY: [Primary breast lymphoma--a report of 27 cases with literature review]. Ai Zheng; 2007 Jan;26(1):84-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary breast lymphoma--a report of 27 cases with literature review].
  • BACKGROUND & OBJECTIVE: Primary breast lymphoma (PBL) is an uncommon disease with poor clinical outcome.
  • RESULTS: Of the 27 patients, 26 were women and 1 was man, with the age ranged from 12 to 84; 18 were at stage IE, 6 at stage IIE, and 3 at stage III/IVE; according to the WHO 2001 lymphoma classification system, 22 had B-cell lymphoma (including 17 cases of diffuse large B-cell lymphoma, 2 cases of mucosa-associated lymphoid tissue lymphoma, 1 case of marginal zone lymphoma, and 2 cases of unclassified B-cell lymphoma), 3 had peripheral T-cell lymphoma, and 2 had unclassified lymphoma.
  • As to the 20 patients with high or moderate grade diseases (diffuse large B-cell lymphoma and peripheral T-cell lymphoma), the 5-year overall and disease-free survival rates were 48% and 27%, respectively.
  • CONCLUSIONS: The main subtypes of PBL are diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222374.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 14
  •  go-up   go-down


58. Sun XF, Zhen ZJ, Lui DG, Xia Y, He YJ, Wang ZH, Lin JY, Guan ZZ: Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. Eur J Haematol; 2006 Nov;77(5):365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
  • OBJECTIVES: This study was designed to evaluate the efficacy and toxicity of the modified B-Non-Hodgkin's Lymphoma (NHL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma.
  • The patients were stratified by risk factors (stage, LDH level and chemotherapy response).
  • Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL).
  • At a median follow up of 24 months, the event free survival (EFS) for all patients was 85% +/- 5% with 100% for group R1, 84% +/- 7% for group R2 and 72% +/- 13% for group R3, and most notably, 80% +/- 6% for stage III/IV at diagnosis.
  • CONCLUSIONS: This modified NHL-BFM-90 protocol is very effective for Chinese children and adolescents with BKL and large cell lymphomas, and represented an increase in the cure rates in childhood NHL in China.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell / drug therapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879606.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


59. Tsavaris N, Kosmas C, Kavantzas N, Lazaris A, Skopelitis E, Dimitrakopoulos A, Siakantaris MP, Papalambros E, Diamantis N, Patsouris E, Pangalis GA: Breast cancer following curative chemotherapy for non-Hodgkin's lymphoma and the effect of drug resistance proteins to the final outcome. A retrospective study. J BUON; 2005 Jan-Mar;10(1):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer following curative chemotherapy for non-Hodgkin's lymphoma and the effect of drug resistance proteins to the final outcome. A retrospective study.
  • PURPOSE: To investigate the overall survival (OS) of patients developing breast cancer (BC) after curative chemotherapy for non-Hodgkin's lymphoma (NHL) and to evaluate the possible effect on the patients' outcome of the expression of drug resistance-related proteins (P-glycoprotein-Pgp, multidrug resistance-associated protein-MRP, and multidrug resistance-related vault lung resistance protein-LRP) in BC issue.
  • PATIENTS AND METHODS: 25 female patients (median age 60 years, range 37-70) who developed BC after chemotherapy for high/intermediate grade B-cell NHL, treated with CHOP and achieving complete remission (CR).
  • A matched-pair group of de novo BC patients formed the control group.
  • In both groups 14 patients had tumor grade II; 16 were negative for steroid receptors; 17 overexpressed c-erbB-2; 14 were stage IIIA/B, and 11 stage IV.
  • There was a better response for stage IV patients in the control versus the study group (p=0.07).
  • More prolonged OS was demonstrate for patients with stage III in the control group (median 51 months) and in subgroup B (median 47 months) than in subgroup A (median 16 months; p=0.00012), as well as for patients with advanced disease (p=0.0045).


60. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • All patients were in clinical stage III or IV.
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group: Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol; 2005 Jun 1;23(16):3793-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
  • PURPOSE: Timing, appropriate amount, and composition of treatment before high-dose therapy and autologous stem-cell transplantation (ASCT) in patients with poor-risk, aggressive non-Hodgkin's lymphoma (NHL) are still unknown.
  • PATIENTS AND METHODS: Between 1994 and 2001, 147 newly diagnosed, poor-risk, aggressive NHL patients, age < or = 65 years with stage III to IV and lactate dehydrogenase (LDH) more than 1.5x upper limit of normal (ULN), entered the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) -27 and HOVON-40 trials.
  • RESULTS: Patient characteristics in both trials were comparable: 80% had diffuse large B-cell lymphoma, 77% had stage IV disease, and median LDH levels were 3.1x ULN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Stem Cell Transplantation. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809447.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


62. Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE, Smith JC, Pagel JM: Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma; 2010 Aug;51(8):1523-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
  • We conducted a multi-center phase II trial of gemcitabine (G), carboplatin (C), dexamethasone (D), and rituximab (R) in order to examine its safety and efficacy as an outpatient salvage regimen for lymphoma.
  • Characteristics included: median age 58 years (19-79 years), stage III/IV 88%, elevated LDH 33%, median prior therapies 2, prior stem cell transplant 12%, chemoresistant 62%, median prior remission duration 2.5 months.
  • The median CD34 yield in patients attempting peripheral blood stem cell (PBSC) collection following this regimen was 10.9 x 10(6) CD34+ cells/kg (range 5.0-24.1 x 10(6)).
  • Hematologic toxicity was common, but febrile neutropenia (2.5%) and grade 4 non-hematologic adverse events (n = 2) were rare, with no treatment-related deaths.
  • GCD(R) is a safe and effective outpatient regimen for relapsed lymphoma, and successfully mobilizes PBSCs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Lymphoma / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Carboplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dexamethasone / administration & dosage. Female. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prospective Studies. Remission Induction. Rituximab. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1456-61 [19224841.001]
  • [Cites] Am J Clin Oncol. 1999 Dec;22(6):550-3 [10597737.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2603-6 [10893292.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Oncology (Williston Park). 2000 Jul;14(7 Suppl 4):26-30 [10960942.001]
  • [Cites] Blood. 2001 Feb 1;97(3):616-23 [11157476.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3918-28 [11579112.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1263-70 [12663713.001]
  • [Cites] Expert Opin Drug Saf. 2003 Nov;2(6):597-607 [14585068.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1762-7 [14630682.001]
  • [Cites] Br J Haematol. 2004 Mar;124(5):645-52 [14871252.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1835-42 [15386331.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):423-31 [1999711.001]
  • [Cites] Biochem Pharmacol. 1993 Aug 17;46(4):762-6 [8363650.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):921-6 [10071285.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1017-22 [16019552.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv18-24 [16702180.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4699-707 [16966687.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1071-9 [17426059.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1363-8 [17496309.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]
  • [Cites] Leuk Lymphoma. 2007 Nov;48(11):2172-8 [17990179.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]
  • [Cites] Clin Breast Cancer. 2008 Oct;8(5):425-31 [18952556.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3786-92 [10577850.001]
  • (PMID = 20578815.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109663-07; United States / NCI NIH HHS / CA / K08 CA095448; United States / NCI NIH HHS / CA / K23 CA085479-06; United States / NCI NIH HHS / CA / R01 CA109663; United States / NCI NIH HHS / CA / R01CA109663; United States / NCI NIH HHS / CA / R01 CA076287; United States / NCI NIH HHS / CA / K23 CA085479; United States / NCI NIH HHS / CA / P01 CA044991; United States / NCI NIH HHS / CA / K23CA85479; United States / NCI NIH HHS / CA / P01 CA044991-22; United States / NCI NIH HHS / CA / R01CA76287; United States / NCI NIH HHS / CA / K08 CA095448-05; United States / NCI NIH HHS / CA / R01 CA076287-14; United States / NCI NIH HHS / CA / P01CA44991; United States / NCI NIH HHS / CA / K08CA095448
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0W860991D6 / Deoxycytidine; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS259899; NLM/ PMC3018339
  •  go-up   go-down


63. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, Poppema S: Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol; 2009 Aug 10;27(23):3815-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.
  • PURPOSE: In classical Hodgkin's lymphoma (cHL), the impact of tumor cell Epstein-Barr virus (EBV) status on clinical outcome is controversial.
  • Tumor cell EBV status was positive in 34%, and the median follow-up time was 7.1 years.
  • Patients' median age at diagnosis was 35 years (range, 7 to 91 years), and 63% had Ann Arbor stage I or II, 24% had stage III, and 12% had stage IV disease.
  • After adjusting for histology, HLA class II expression by tumor cells, stage, presence of extranodal localizations and treatment, and the effect of positive EBV tumor status remained significant in FFS multivariate analysis (hazard ratio, 3.11; 95% CI, 1.28 to 7.53; P = .01).
  • CONCLUSION: This study indicates that treatment failure in older adult patients with cHL is associated with positive tumor cell EBV status.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470931.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Wolf R, Barzilai A, Davidovici B: Intertriginous lymphomatoid drug eruption. Int J Dermatol; 2010 Oct;49(10):1207-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two days before the eruption appeared, he had received a second course of chemotherapy consisting of cisplatinum 40 mg and gemcitabine (Gemzar) 1700 mg for the treatment of squamous cell carcinoma of the lung stage III B.
  • Our case is interesting and unusual in that it demonstrated a rare clinical presentation of drug eruption, namely, intertriginous drug eruption or baboon syndrome, with a histologic picture of a lymphomatoid drug eruption that can mimic lymphoma.

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 The International Society of Dermatology.
  • (PMID = 20883412.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


65. Qi L, Cazares L, Johnson C, de Alarcon P, Kupfer GM, Semmes OJ: Serum protein expression profiling in pediatric Hodgkin lymphoma: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Aug;51(2):216-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein expression profiling in pediatric Hodgkin lymphoma: a report from the Children's Oncology Group.
  • BACKGROUND: The prognosis for children with Hodgkin lymphoma (HL) treated with a risk adjusted combination of radiation therapy and multi-drug chemotherapy has markedly improved.
  • The current stage-based risk assignment of HL cannot predict the patients within a risk group that are destined to recur or do not respond to therapy.
  • PROCEDURE: We have completed a preliminary project to identify characteristic serum protein peaks determined by protein expression profiling in serum of 22 subjects with HL, 13 with stage II HL and 9 with stage III or IV.
  • RESULTS: Protein profiling successfully discriminated between high grade (III/IV) HL and low grade (II) HL.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421715.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA85067; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / alpha 1-Antitrypsin
  •  go-up   go-down


66. Guo Y, Lu JJ, Ma X, Wang B, Hong X, Li X, Li J: Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol; 2008 Jan;44(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
  • The objective of this analysis was to evaluate the efficacy and treatment outcome of CHOP and CHOP combined with nitrosourea chemotherapy in natural killer (NK)/T-cell lymphoma of the nasal cavity.
  • Sixty-three patients with NK/T-cell lymphoma of the nasal cavity were treated with CHOP or CHOP combined with oral nitrosourea chemotherapy between January 1997 and June 2005.
  • By the Ann Arbor Lymphoma Staging Classification, 57 patients (90%) had Stage IE or IIE disease and six patients (10%) had Stage III or IV disease.
  • All patients with Stage IE or IIE disease were intended to be treated curatively with combined chemoradiation; and patients who had Stage III or IV disease were treated with chemotherapy alone with curative intention.
  • External beam radiation therapy was delivered by daily conventional fractionation by Co-60 or 6MVx linear accelerator for patients with Stage IE or IIE disease.
  • Nine patients with Stage IE or IIE diseases developed disease progression during their planned treatment and died within 10 months after the initiation of treatment; Six patients who achieved complete response (CR) after planned chemoradiation developed systemic recurrence and died at 13-48 months despite salvage treatment; one patient died of Hemophagocytic Syndrome during radiotherapy after achieving CR from chemotherapy.
  • Three patients with Stage III or IV disease died during chemotherapy or during salvage treatment at 2, 4, and 19 months, respectively.
  • Multivariate analysis revealed that International Prognostic Index (IPI) for Lymphoma, perforation of nasal septum as a presenting symptom, "B" symptoms, ECOG performance, as well as response after chemotherapy, were significant independent prognostic factors for this group of patients.
  • The extent of response after induction chemotherapy is significantly related to the treatment outcome of patients with nasal NK/T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Extranodal NK-T-Cell / drug therapy. Nose Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Semustine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306611.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 13909-09-6 / Semustine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


67. Xu G, Wang H, He G, Chen D: [Expressions of p53 and p21 in nasal NK/T-cell lymphoma and their relationship with the proliferation and apoptosis of cells]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jan;23(2):73-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of p53 and p21 in nasal NK/T-cell lymphoma and their relationship with the proliferation and apoptosis of cells].
  • OBJECTIVE: To investigate the significance of expressions of p53 and p21 in nasal NK/T-cell lymphoma (NKTL) and their relationship with cell proliferation and apoptosis.
  • The positive expression rates of p53 in Ann Arbor stage I, II, III and IV NKTL were 69.57%, 75%, 86.67% and 100% respectively, while those of p21 were 47.83%, 56.25%, 60% and 87.50%.
  • The intensity of p53 and p21 expression, the Ann Arbor stage and the size of tumor cell all were positively correlated with PI (Spearman correlation analysis, P<0.05), while no correlation with AI (P>0.05).
  • [MeSH-major] Apoptosis. Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Lymphoma, Extranodal NK-T-Cell / pathology. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452712.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


68. Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K, Aydogdu I: Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm; 2005 Aug 14;2005(3):171-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age of the patients was 63.4 +/- 10.8 years and all of the patients were stage III (classified according to the Durie-Salmon classification).

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):21-8 [11707866.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2584-92 [11971193.001]
  • [Cites] Clin Lab Haematol. 2003 Feb;25(1):41-6 [12542441.001]
  • [Cites] Eur J Haematol. 2003 Jan;70(1):34-42 [12631257.001]
  • [Cites] Cancer. 2003 May 15;97(10):2440-52 [12733143.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):455-7 [12845688.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):106-13 [12953803.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3368-75 [15021914.001]
  • [Cites] Cytokine. 2004 May 21;26(4):145-8 [15149630.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2312-6 [15150588.001]
  • [Cites] Curr Hematol Rep. 2004 Jul;3(4):249-56 [15217554.001]
  • [Cites] Bone Marrow Transplant. 2004 Jul;34(2):161-7 [15133489.001]
  • [Cites] BioDrugs. 2004;18(4):269-78 [15244502.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):475-86 [15287939.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:3085-90 [15353339.001]
  • [Cites] Clin Exp Immunol. 1991 Jun;84(3):429-34 [2044221.001]
  • [Cites] Clin Exp Immunol. 1993 Apr;92(1):27-31 [8467562.001]
  • [Cites] J Leukoc Biol. 1995 May;57(5):752-62 [7539029.001]
  • [Cites] Cancer Detect Prev. 1996;20(1):52-6 [8907203.001]
  • [Cites] Eur J Clin Invest. 1998 Aug;28(8):679-86 [9767364.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):350-7 [10050719.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1117-25 [10626139.001]
  • [Cites] Annu Rev Immunol. 2000;18:217-42 [10837058.001]
  • [Cites] Eur J Haematol. 2000 Feb;64(2):121-9 [10997332.001]
  • [Cites] Semin Hematol. 2001 Apr;38(2 Suppl 3):15-20 [11309704.001]
  • (PMID = 16106104.001).
  • [ISSN] 0962-9351
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Receptors, Interleukin-2; 0 / Tumor Necrosis Factor-alpha; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 9007-41-4 / C-Reactive Protein; VAD protocol
  • [Other-IDs] NLM/ PMC1526466
  •  go-up   go-down


69. Vonderheid EC, Pena J, Nowell P: Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leuk Lymphoma; 2006 Sep;47(9):1841-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging.
  • In this retrospective study, quantitative Sézary cell counts were performed at presentation on 192 patients with erythrodermic cutaneous T-cell lymphoma (E-CTCL).
  • Per recommendation of the International Society of Cutaneous Lymphomas (ISCL), the impact on staging of using an absolute Sézary cell count of 1.0 K microL-1 or more as equivalent to lymph node involvement was investigated.
  • Of 132 patients with disease initially classified at stage III using the current TNM staging system, 25% were up staged to IVa, resulting in a clearer separation of associated survival curves between the stages.
  • Furthermore, the current ISCL definition of B0, B1 and B2 ratings were improved using Sézary cell count levels of < 1.0 K microL-1, > or = 1.0 - 4.99 K microL-1 and > or = 5.0 K microL-1, respectively.
  • [MeSH-major] Dermatitis, Exfoliative / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis. Sezary Syndrome / blood. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Female. Humans. Lymph Nodes. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064997.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


70. Kwong YL: High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant; 2009 Dec;44(11):709-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies.
  • Natural killer (NK)-cell lymphomas are aggressive.
  • Patients with early (stage I/II) diseases respond favorably to radiotherapy and chemotherapy.
  • Patients with relapses and advanced (stage III/IV) diseases have poor outcome.
  • To evaluate the efficacy of allogeneic HSCT, optimal conditioning regimens and a clear graft-versus-lymphoma effect should be defined.
  • HSCT is a potential option in NK-cell lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Extranodal NK-T-Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767784.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


71. Schüler F, Dölken L, Hirt C, Kiefer T, Berg T, Fusch G, Weitmann K, Hoffmann W, Fusch C, Janz S, Rabkin CS, Dölken G: Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer; 2009 Feb 15;124(4):958-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The t(14;18) translocation is a common genetic aberration that can be seen as an early step in pathogenesis of follicular lymphoma (FL).
  • The significance of low level circulating t(14;18)-positive cells in healthy individuals as clonal lymphoma precursors or indicators of risk is still unclear.
  • Four percent (31/715) of individuals carried more than one t(14;18)-positive cell per 25,000 peripheral blood mononuclear cells (PBMNCs).
  • In comparison, 108 stage III/IV FL patients had a median number of circulating t(14;18)-positive malignant FL cells of about 9200/1 million PBMNCs (range 7-1,000,000).
  • These findings will further improve the understanding of the relevance of t(14;18)-positive cells in healthy individuals as a risk marker toward the development into lymphoma precursors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Child. Child, Preschool. Humans. Infant. Infant, Newborn. Lymphoma, Follicular / genetics. Middle Aged. Prevalence. Proto-Oncogene Proteins c-bcl-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19030176.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA151354
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ NIHMS638971; NLM/ PMC4216731
  •  go-up   go-down


72. Glance LE, Cumpston A, Kanate A, Remick SC: Bendamustine-associated hemolytic anemia. Ann Pharmacother; 2009 Nov;43(11):1903-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 64-year-old white female had recently received treatment with bendamustine for stage III follicular lymphoma.
  • A bone marrow biopsy showed no evidence of lymphoma and presence of megakaryocytes on 2 occasions.
  • DISCUSSION: Drug-induced hemolytic anemia is an acquired or extrinsic process that results in antibody-mediated red blood cell destruction.

  • Genetic Alliance. consumer health - Anemia.
  • Hazardous Substances Data Bank. Bendamustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19809007.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  •  go-up   go-down


73. Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, Kupper TS: Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood; 2007 Oct 15;110(8):3015-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome.
  • Cutaneous T-cell lymphoma (CTCL) is defined by infiltration of activated and malignant T cells in the skin.
  • Of these, 2 clusters tended to differentiate limited CTCL (stages IA and IB) from more extensive CTCL (stages IB and III).
  • Stage IB patients appeared in both clusters, but those in the limited CTCL cluster were more responsive to treatment than those in the more extensive CTCL cluster.
  • The third cluster was enriched in lymphocyte activation genes and was associated with a high proportion of tumor (stage IIB) lesions.
  • Using supervised analysis, we further characterized genes significantly associated with lower-stage/treatment-responsive CTCL versus higher-stage/treatment-resistant CTCL.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2003 May 1;19(7):891-2 [12724301.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1539-44 [12707037.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1042-50 [12689942.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):857-66 [12873880.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4059-66 [12829591.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):211-22 [15039758.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Jul;18(4):397-415 [15196152.001]
  • [Cites] Blood. 2004 Aug 15;104(4):923-32 [15155462.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] J Cell Biol. 1984 Apr;98(4):1397-406 [6201492.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3050-9 [7579399.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1150-9 [9694702.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1680-3 [9733516.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Nat Immunol. 2005 Jan;6(1):90-8 [15568026.001]
  • [Cites] Immunol Cell Biol. 2005 Feb;83(1):33-9 [15661039.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5378-90 [15579466.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Genes Chromosomes Cancer. 2005 May;43(1):1-10 [15672409.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):798-812 [15841167.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5748-55 [16115912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1439-46 [16424171.001]
  • [Cites] J Invest Dermatol. 2006 Apr;126(4):869-81 [16470182.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2463-72 [16760446.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1924-5 [16709585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):418-25 [10071312.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1477-88 [12782714.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):299-306 [10951250.001]
  • [Cites] Dermatology. 2000;201(1):21-8 [10971054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Mayo Clin Proc. 2002 Sep;77(9):927-40 [12233926.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3279-86 [12384428.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1825-37 [12414529.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [ErratumIn] Blood. 2008 Jan 1;111(1):49
  • (PMID = 17638852.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA093683
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2018675
  •  go-up   go-down


74. Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J, White VA: Mantle cell lymphoma in the ocular adnexal region. Ophthalmology; 2005 Jan;112(1):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma in the ocular adnexal region.
  • PURPOSE: To study the clinicopathologic features of mantle cell lymphoma (MCL) in the ocular adnexal region.
  • Six of the 10 patients died, all of lymphoma.
  • The orbit (90%) was most commonly involved followed by the lacrimal gland (50%) and lid (50%), with 90% of cases having lymphoma present at 2 or more periocular sites.
  • Most had a primary periocular presentation (80%) that was associated with stage III/IV disease (80%), including atypical cells in the peripheral blood smear (60%) and bone marrow involvement (70%) at presentation.
  • Three cases were CD5-negative, and 2 other cases showed composite histologic findings (MCL and follicular lymphoma and MCL and a plasma cell neoplasm).
  • CONCLUSIONS: Mantle cell lymphoma presenting in the ocular adnexal region has a male predominance and tends to affect an elderly age group, as is typical of MCL involving nodal sites.
  • Mantle cell lymphoma presenting in the ocular adnexal region is associated with advanced-stage disease and short PFS but an OS similar to MCL at other sites.
  • [MeSH-major] Eye Neoplasms / pathology. Eyelid Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Lymphoma, Mantle-Cell / pathology. Orbital Neoplasms / pathology


75. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS: Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol; 2010 Sep 20;28(27):4170-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
  • PURPOSE: The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
  • Variables including age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs) on positron emission tomography (PET), International Prognostic Index (IPI), and Ki67 staining (proliferation).
  • RESULTS: Of 469 patients, 190 (40.5%) had stage I or II disease and 279 (59.5%) had stage III or IV disease, 327 (70%) had at least six cycles of R-CHOP, and 142 (30.2%) had involved-field RT (dose, 30 to 39.6 Gy) after complete response to chemotherapy.
  • Matched-pair analyses of patients who received six to eight cycles of R-CHOP with stage I or II disease (44 pairs) and all stages (74 pairs) indicated that RT improved OS (hazard ratio [HR], 0.52 and 0.29, respectively) and PFS (HR, 0.45 and 0.24, respectively) compared with no RT.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Prednisone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cell Proliferation. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Matched-Pair Analysis. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Survival Analysis. Texas. Time Factors. Treatment Outcome. Young Adult


76. Choi JW, An JS, Lee JH, Lee ES, Kim KH, Kim YS: Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma. Mod Pathol; 2006 Jul;19(7):963-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma.
  • The expression of TIMP-1 is known to be correlated with a subset of non-Hodgkin lymphoma at the mRNA level, and Epstein-Barr virus infection in vitro.
  • To characterize TIMP-1(+) diffuse large B-cell lymphoma, TIMP-1 expression was investigated in tissue microarrays from 182 cases of de novo diffuse large B-cell lymphoma and compared with prognostic factors, immunophenotypes, and Epstein-Barr virus infection status.
  • TIMP-1 was expressed not only in tumor cells themselves, in 14 of 182 cases (8%), designated as TIMP-1(+) diffuse large B-cell lymphoma, but also in stromal cells like fibroblasts and endothelial cells.
  • In multivariate analysis, TIMP-1(+) diffuse large B-cell lymphoma (n=14) was associated with unfavorable outcomes compared to TIMP-1(-) diffuse large B-cell lymphoma (n=168) (odds ratio=2.5, P=0.049).
  • Together with TIMP-1 expression, age (greater than 60 years), the presence of B-symptoms, abnormal lactate dehydrogenase level, or more advanced stage (III/IV) was correlated with a poor overall survival.
  • However, TIMP-1 expression in diffuse large B-cell lymphoma was not correlated with other prognostic factors including: clinical stage, international prognostic index score, and nongerminal center B-cell phenotype, as well as Epstein-Barr virus infection.
  • Our results suggest that TIMP-1 expression may be an independent negative prognostic factor in patients with diffuse large B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648868.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


77. Xu Y, McKenna RW, Doolittle JE, Hladik CL, Kroft SH: The t(14;18) in diffuse large B-cell lymphoma: correlation with germinal center-associated markers and clinical features. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):116-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The t(14;18) in diffuse large B-cell lymphoma: correlation with germinal center-associated markers and clinical features.
  • The clinical and biologic relevance of the t(14;18) and features of germinal center (GC) differentiation in diffuse large B-cell lymphoma (DLBCL) remain controversial.
  • The authors examined the association of t(14;18) with GC-associated markers and clinical features in 44 de novo DLBCLs (22 nodal and 22 primary extranodal).
  • A CD10+/bcl-6+ phenotype was not significantly associated with bcl-2 expression, stage, complete remission rate, or survival.
  • It was associated with a CD10+/bcl-6+ phenotype (5 of 7 vs. 7 of 27; P = 0.015) and a trend toward more frequent bcl-6 expression (6 of 7 vs. 15 of 34; P = 0.09), but no association with bcl-2 expression, CD10, clinical stage, complete remission, or survival.
  • Among nodal or high-stage (III-IV) DLBCL, cases with the t(14;18) showed a trend toward decreased survival (P = 0.12).

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894922.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


78. Butt FM, Chindia ML, Rana F, Machigo FG: Pattern of head and neck malignant neoplasms in HIV-infected patients in Kenya. Int J Oral Maxillofac Surg; 2008 Oct;37(10):907-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most commonly reported neoplasms of the head and neck region include Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL).
  • There is also an increased risk of oral squamous cell carcinoma (SCC).
  • A descriptive cross-sectional study including HIV-infected patients with neoplastic and non-neoplastic lesions was conducted.
  • The prevalence of neoplastic lesions in this study was 27%; 37 (68%) patients had KS, 9 (17%) had SCC, 7 (13%) had NHL and 1 (2%) had Burkitt's lymphoma.
  • Most study participants (97%) were in stage III/IV of the disease and the remaining 3% in stage II.
  • In this study, the most common malignant neoplasms were KS, SCC and NHL, manifesting in a younger age group than in the non-HIV group of patients.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Burkitt Lymphoma / epidemiology. Candidiasis, Oral / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cheilitis / epidemiology. Cross-Sectional Studies. Female. Humans. Kenya / epidemiology. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Prevalence. Sarcoma, Kaposi / epidemiology. Sex Factors. Stomatitis, Aphthous / epidemiology. Young Adult


79. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS, Children's Oncology Group: Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol; 2008 Oct;143(2):261-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group.
  • Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy.
  • Between July 1994 and June 1997, 85 eligible children and adolescents with advanced LL (Stage III/IV) were enrolled on this pilot study.
  • Grade III/IV toxicities included: hematological (80%), infections (20%), stomatitis and elevated transaminases, (29%).

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):840-6 [18342502.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):537-41 [6689428.001]
  • [Cites] Br J Cancer. 1984 Oct;50(4):457-62 [6333247.001]
  • [Cites] Blood. 1985 Nov;66(5):1110-4 [3840395.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):744-52 [3517244.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Br J Haematol. 1992 Oct;82(2):310-6 [1419812.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):130-40 [16358311.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • (PMID = 18759768.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / U10 CA098543-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS107033; NLM/ PMC3057023
  •  go-up   go-down


80. Wu HB, Wang QS, Wang MF, Li HS, Zhou WL, Ye XH, Wang QY: Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun; 2010 Mar;31(3):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas.
  • PURPOSE: Extranodal natural killer (NK)/T-cell lymphoma is a rare neoplasm and limited data has reported regarding the utilization of fluorine-18, fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) in this disease.
  • The aim of this study was to assess the role of F-FDG PET/CT in the staging of NK/T-cell lymphomas.
  • PATIENTS AND METHODS: Thirteen newly diagnosed and two recurrent patients with NK/T-cell lymphoma who received F-FDG PET/CT were studied.
  • RESULTS: F-FDG PET/CT detected nasal or extranasal lymphoma lesions in at least one site in all of the 15 patients.
  • There was no significant difference of F-FDG uptake in lesions between patients with stage I-II disease and those with stage III-IV disease (maximal standardized uptake values 8.44+/-5.56 vs. 10.32+/-7.80; t=0.757, P>0.05).
  • In two patients with an indeterminate diagnosis, the diagnosis of NK/T-cell lymphomas was established by biopsy guided by PET/CT and the status of stage IV was correctly identified.
  • In 13 patients with definite diagnosis, the stage of disease was changed in six patients on the basis of F-FDG PET/CT.
  • CONCLUSION: The lesions of the NK/T-cell lymphoma are F-FDG avid and PET/CT seems to be useful in the staging of this disease.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, T-Cell / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009963.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


81. Maeshima AM, Omatsu M, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y: Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses. Cancer Sci; 2008 Sep;99(9):1760-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses.
  • Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin lymphoma and frequently transforms to diffuse large B-cell lymphoma (DLBCL).
  • Most of the patients (34/43) showed advanced-stage (III or IV) disease initially.
  • Among the DLBCLs, 84% were classified as the germinal center B-cell phenotype (GCB) and 16% as non-GCB in accordance with the criteria of Hans et al. IGH/BCL2 fusion was detected by FISH in 89% of FLs and 82% of DLBCLs.
  • [MeSH-major] Cell Transformation, Neoplastic. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549405.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


82. Park SR, Baek JY, Kim DW, Im SA, Kim TY, Bang YJ, Kim NK, Jeon YK, Kim CW, Heo DS: Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. J Korean Med Sci; 2006 Aug;21(4):633-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.
  • Despite advances in the characterization of anaplastic large cell lymphoma (ALCL), little data is available on Asian patients.
  • Ann Arbor stage III-IV, B symptoms, high-intermediate/ high International Prognostic Index (IPI), and extranodal disease at diagnosis were present in 56%, 44%, 41%, and 63%, respectively.
  • The staining results for anaplastic lymphoma kinase were positive in 6 (33%) of 18 cases available.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Large-Cell, Anaplastic / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Nov 1;90(9):3727-34 [9345059.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S56-67 [9894470.001]
  • [Cites] Aust N Z J Med. 1998 Dec;28(6):790-4 [9972408.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2688-96 [10194449.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Haematologica. 1999 May;84(5):425-30 [10329921.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1727-31 [14692525.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):23-33 [2456620.001]
  • [Cites] Br J Haematol. 1989 Jan;71(1):31-6 [2917127.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2604-12 [8453584.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):937-42 [8387578.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):513-23 [7519036.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):955-62 [8622045.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):319-27 [8819081.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1420-32 [9414185.001]
  • (PMID = 16891805.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Other-IDs] NLM/ PMC2729883
  •  go-up   go-down


83. Ji H, Li GD, Li FY, Bai YQ, Chen Y, Yang MZ, Wang LJ, Tang Y, Zhang P, Xia T, Li C, Feng J, Zou ZK, Yixi JC: [Mantle cell lymphoma: clinicopathologic features and prognostic factors of 102 cases occurring in Chinese patients]. Zhonghua Bing Li Xue Za Zhi; 2007 Nov;36(11):730-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mantle cell lymphoma: clinicopathologic features and prognostic factors of 102 cases occurring in Chinese patients].
  • OBJECTIVE: To study the clinicopathologic features and prognostic factors of Chinese patients with mantle cell lymphoma.
  • METHODS: One hundred and two cases of mantle cell lymphoma occurring in Chinese patients were studied by light microscopy and immunohistochemistry.
  • Seventy-one patients (87.65%) presented with advanced stage disease (Ann Arbor stage III to IV).
  • All cases expressed B-cell markers but were negative for T-cell marker.
  • CONCLUSIONS: The clinicopathologic features and prognostic factors of mantle cell lymphoma occurring in Chinese are similar to those in Caucasians.
  • [MeSH-major] Cyclin D1 / metabolism. Lymphoma, Mantle-Cell / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307875.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD5; 0 / Antigens, CD79; 136601-57-5 / Cyclin D1; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


84. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, BFM Group: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood; 2005 Feb 1;105(3):948-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
  • In the Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster 95 (NHL-BFM95) study, we tested by randomization whether for patients with B-cell neoplasms methotrexate as intravenous infusion over 4 hours (MTX-4h) is not inferior to, but less toxic than, a 24-hour intravenous infusion (MTX-24h).
  • Incidence of mucositis grade III/IV was significantly lower with MTX-4h in all risk groups.
  • MTX-4h was noninferior to MTX-24h for limited stage B-cell non-Hodgkin lymphoma (B-NHL) but not for advanced disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Methotrexate / administration & dosage. Methotrexate / therapeutic use

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486066.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


85. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA: Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol; 2010 Mar;183(3):915-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most histological subtypes were more common in males except squamous cell carcinoma and lymphoma.
  • Muscle invasion was seen in 52.2% of urothelial carcinoma cases vs 87.5%, 71.9% and 89.0% of squamous cell carcinoma, adenocarcinoma and neuroendocrine tumor cases, respectively.
  • For urothelial carcinoma, squamous cell carcinoma and adenocarcinoma women presented at more advanced stage.
  • In the neuroendocrine group this stage difference was the opposite.
  • Survival analysis showed a 5-year relative survival rate of 32.2%, 22.9%, 31.8% and 21.1% for T2 or greater urothelial carcinoma, squamous cell carcinoma, adenocarcinoma and neuroendocrine tumors, respectively.
  • CONCLUSIONS: Patients with nonurothelial carcinoma present at more advanced stage and overall have worse survival.
  • For stage II and III disease these cases do even better.
  • Muscle invasive squamous cell carcinoma and neuroendocrine tumors show worse survival regardless of stage.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] J Urol. 2010 Mar;183(3):920 [20083283.001]
  • (PMID = 20083267.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Oh SY, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ: Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. Eur J Haematol; 2007 Oct;79(4):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease.
  • Intestinal marginal zone B-cell lymphoma of the MALT type (I-MZL) is a relatively uncommon form of lymphoma.
  • Musshoff's stage I(E), II(E)1, II(E)2, III(E) and IV were present in 44%, 15%, 11%, 7.4% and 22% respectively.
  • Sixty-three percent were in the low-risk group according to the Follicular Lymphoma International Prognostic Index.
  • Stage > or = II(E)2 was determined to be a poor prognostic factor for PFS and OS.
  • I-MZL commonly manifests in an early-stage, low-risk state and tends to respond well to local and systemic treatment with favorable prognosis.
  • [MeSH-major] Cecal Neoplasms / mortality. Ileal Neoplasms / mortality. Lymphoma, B-Cell, Marginal Zone / mortality. Rare Diseases / mortality

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692101.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


87. Knight C, Maciver F: The cost-effectiveness of rituximab in non-Hodgkin's lymphoma. Expert Rev Pharmacoecon Outcomes Res; 2007 Aug;7(4):319-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cost-effectiveness of rituximab in non-Hodgkin's lymphoma.
  • Rituximab is indicated: as the first-line treatment of diffuse-large B-cell non-Hodgkin's lymphoma (NHL) in combination with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); as the first-line treatment of stage III-IV follicular NHL in combination with cyclophosphamide, vincristine and prednisolone (CVP); for the treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or in their second or subsequent relapse after chemotherapy; and as maintenance therapy for patients with relapsed/refractory follicular lymphoma responding to induction therapy with chemotherapy with or without rituximab.
  • The conclusion of these analyses is that rituximab, used both as monotherapy and in combination with chemotherapy, is a cost-effective intervention in the most common forms of NHL, diffuse large B-cell lymphoma and follicular NHL.
  • If it has the same clinical success in these trials as it has had in diffuse large B-cell lymphoma and follicular lymphoma, then it is possible that within a few years rituximab could play a key role in treating patients in all forms of NHL.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528413.001).
  • [ISSN] 1744-8379
  • [Journal-full-title] Expert review of pharmacoeconomics & outcomes research
  • [ISO-abbreviation] Expert Rev Pharmacoecon Outcomes Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M: Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk; 2010 Aug;10(4):258-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
  • BACKGROUND: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database.
  • A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease.
  • According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma.
  • All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (>or= 3 previous treatments), and 2 had had autologous stem cell transplantation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20709661.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


89. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol; 2009 Mar 10;27(8):1209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of deferred initial therapy in mantle-cell lymphoma.
  • PURPOSE: Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though patients are commonly treated immediately at diagnosis.
  • Prognostic factors in assessable patients included advanced stage (III/IV) in 75%, elevated lactate dehydrogenase in 25%, and intermediate- or high-risk Mantle Cell International Prognostic Index in 54%.
  • [MeSH-major] Lymphoma, Mantle-Cell / drug therapy


90. Li YX, Fang H, Liu QF, Lu J, Qi SN, Wang H, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Feng XL, Yu ZH: Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood; 2008 Oct 15;112(8):3057-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring.
  • The clinical characteristics and prognosis remain unclear for nasal-type NK/T-cell lymphoma of Waldeyer ring (WR-NKTL).
  • According to the Ann Arbor system, 15, 56, 12, and 8 patients had stage I, II, III, and IV.
  • Of patients with stage I and II, 54 received combined chemotherapy and radiotherapy (CMT), 13 received radiotherapy alone, and 4 patients received chemotherapy alone.
  • All 20 patients with stage III/IV received primary chemotherapy.
  • The disease is characterized by predominance in young males, good performance, a propensity for nodal involvement, frequent stage II through IV diseases, low frequency of elevated LDH, low-risk international prognostic index (IPI), high sensitivity to radiotherapy, and intermediate sensitivity to chemotherapy.
  • The age, B symptoms, stage, and IPI were important prognostic factors.
  • CMT tended to improve the survival compared with radiotherapy alone for patients with stage I and II diseases.
  • [MeSH-major] Killer Cells, Natural / cytology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Nose Neoplasms / diagnosis. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676879.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


91. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • Initial stage I:II:III:IV:unknown was 15:34:33:42:3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


92. Gudgin E, Rashbass J, Pulford KJ, Erber WN: Primary and isolated anaplastic large cell lymphoma of the bone marrow. Leuk Lymphoma; 2005 Mar;46(3):461-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and isolated anaplastic large cell lymphoma of the bone marrow.
  • Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma in which the majority of patients present with advanced stage III or IV disease.
  • Genetics confirmed the clonal nature of the disease and showed it to be anaplastic lymphoma kinase (ALK) negative.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, Large-Cell, Anaplastic / pathology


93. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol; 2005 Jun 20;23(18):4079-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Fludarabine and cyclophosphamide (FC), which are active in treatment of chronic lymphocytic leukemia (CLL), are synergistic with the monoclonal antibody rituximab in vitro in lymphoma cell lines.
  • RESULTS: The median age was 58 years; 75 patients (33%) had Rai stage III to IV disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Curr Hematol Malig Rep. 2006 Mar;1(1):41-2 [20425330.001]
  • [CommentIn] J Clin Oncol. 2005 Jun 20;23(18):4009-12 [15767640.001]
  • (PMID = 15767648.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


94. Hurvitz SA, Timmerman JM: Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol; 2005 Sep;17(5):432-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
  • PURPOSE OF REVIEW: Therapeutic vaccines targeting B cell lymphoma idiotype have reached an advanced stage of clinical development, with three multicenter randomized clinical trials ongoing.
  • This review describes the rationale and development of this immunotherapeutic approach, the design of current phase III trials, and other active vaccination approaches likely to move forward into clinical testing for lymphomas.
  • A third trial opened in 2004, using rituximab followed by idiotype vaccine with maintenance booster vaccines continuing throughout the period of normal B cell recovery.
  • SUMMARY: Lymphoma idiotype vaccination represents a promising immunotherapeutic approach targeting a patient-specific tumor antigen.
  • The results of pivotal phase III trials for three first-generation idiotype vaccines will become available in the next several years.
  • Advanced manufacturing techniques should permit application of this tailor-made treatment to large numbers of non-Hodgkin's lymphoma patients.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Vaccines, DNA / therapeutic use
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Humans. Immunoglobulin Idiotypes / therapeutic use. Immunotherapy / trends

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093791.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Immunoglobulin Idiotypes; 0 / Vaccines, DNA
  • [Number-of-references] 82
  •  go-up   go-down


95. van Grotel M, Lam KH, de Man R, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM: High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma; 2006 Aug;47(8):1504-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
  • Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children.
  • Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately.
  • NLPHL patients were stage I (n = 5), II (n = 2), whereas cHL, median age 11.4 years (range 3.3 - 15.9 years), were stage I (n = 8), II (n = 17), III (n = 9), IV (n = 1).
  • One patient relapsing with stage III disease was salvaged by EBVD/MOPP followed by autologous BMT and is also in second CR for 36 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Aug;47(8):1450-1 [16966251.001]
  • (PMID = 16966260.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


96. Micallef IN, Remstein ED, Ansell SM, Colgan JP, Inwards DJ, Johnston PB, Lewis JT, Markovic SN, Porrata LF, White WL, Witzig TE, Ristow K, Habermann TM: The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leuk Lymphoma; 2006 Sep;47(9):1794-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma.
  • Histological transformation of low-grade non-Hodgkin lymphoma (NHL) to diffuse large cell NHL is well recognized and is associated with a poor prognosis.
  • Between November 1979 and September 2000, 93 patients who developed transformed lymphoma were identified.
  • Seventy-eight percent had stage III or IV disease.
  • On univariate analysis, the following factors at the time of histological transformation were associated with an improved survival: low tIPI (P = 0.009), time to transformation > 4 years (P = 0.02), age < or = 60 years (P = 0.02) and stage I or II disease (P = 0.04).
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064990.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Rasmussen P, Sjö LD, Prause JU, Ralfkiaer E, Heegaard S: Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol; 2009 Aug;93(8):1047-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma in the orbital and adnexal region.
  • AIMS: To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region.
  • METHODS: Data on lymphoid lesions were retrieved searching the Danish Ocular Lymphoma Database 1980-2005.
  • RESULTS: Twenty-one patients with MCL in the orbital and adnexal region were identified comprising 9% (21/230) of all lymphoma in the ocular region.
  • All but two presented in stage III/IV.
  • Most patients presented with stage IV disease and had multiple relapses and short survival time.
  • [MeSH-major] Eye Neoplasms / pathology. Lymphoma, Mantle-Cell / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Orbital lymphoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19429588.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. Liu YH, Zhuang HG, Lin HL, Wu QL, Luo DL, Luo XL: [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis]. Zhonghua Bing Li Xue Za Zhi; 2005 Dec;34(12):771-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis].
  • OBJECTIVE: To study the histology, immunophenotype and differential diagnosis of T-cell/histiocyte-rich B-cell lymphoma (TCRBCL).
  • METHODS: A review of 245 cases of so-called Hodgkin lymphoma diagnosed during the period from 1980 to 2000 in 3 hospitals in Guangzhou, 8 cases were reclassified as TCRBCL, according to the 2001 World Health Organization classification of lymphoid neoplasms.
  • Immunohistochemical studies were performed on paraffin-embedded tissue by SP technique in order to study the immunophenotype of the large neoplastic cells (CD20, CD79a, CD3, CD45RO, CD15, CD30, CD10, bcl-6 and EMA) and background non-neoplastic cells (CD3, CD8, CD20, CD45RO, CD79a, CD57, CD68, CD21, CD35, cyclin D1, TIA-1).
  • On presentation, 3 cases belonged to stage II, 10 cases stage III and 3 cases stage IV.
  • The histiocytic cells were CD68-positive; and CD21 and CD35-positive follicular dendritic cell meshworks were absent.
  • CONCLUSIONS: TCRBCL is a rare subtype of lymphoma, with distinctive histology and immunophenotype.
  • The above features are helpful in delineating this entity from Hodgkin lymphoma, reactive lymphoid hyperplasia and lymphomatoid granulomatosis.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD79 / metabolism. Child. Diagnosis, Differential. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Staging. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545182.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / Mucin-1
  •  go-up   go-down


99. Stark B, Avigad S, Luria D, Manor S, Reshef-Ronen T, Avrahami G, Yaniv I: Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer; 2009 Jan;52(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
  • BACKGROUND: Despite overlapping features of T-cell lymphoblastic lymphoma (T-LLy) and T-cell acute lymphoblastic leukemia (T-ALL), which respond favorably to T-ALL treatment, clinical and biological differences exist.
  • We retrospectively assessed the prevalence of submicroscopic bone marrow (BM) minimal disseminated disease (MDD) at diagnosis and the early response to treatment (minimal residual disease--MRD) and their prognostic significance in 17 children with stage III T-LLy treated according to Berlin-Frankfurt-Munster (BFM) non-Hodgkin lymphoma protocols.
  • PROCEDURE: Four-color flow cytometry (FC) was used for lymphoma associated immunophenotype and real-time quantitative polymerase chain reaction (RQ-PCR) for T-cell receptor (TCR beta/delta/gamma) gene rearrangements with at least 0.01% sensitivity.
  • CONCLUSIONS: MDD was prevalent in stage III T-LLy, for which we could not prove a prognostic significance in the context of ALL-like treatment.
  • [MeSH-major] Bone Marrow Diseases / diagnosis. Neoplasm, Residual / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Pan Y, Li GD, Liu WP, Zhang WY, Tang Y, Li FY: [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients]. Zhonghua Bing Li Xue Za Zhi; 2009 Dec;38(12):810-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
  • OBJECTIVE: To study the clinicopathologic features, immunohistochemical findings and prognosis of precursor lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL).
  • The pathologic findings were correlated with Ann Arbor tumor stage, Ki-67 index, other clinical parameters (including mediastinum/bone marrow involvement, hepato-splenomegaly, age and gender of the patients) and the survival data.
  • The cases were categorized into three groups according to the immunohistochemical findings, as follows: precursor T-cell, precursor B-cell and undefined.
  • Ninety-one cases (85.8%) were in stage III or IV at diagnosis.
  • Patients older than 25 years and those presented in stage III or IV suggested a poor prognosis (P = 0.049 and 0.001, respectively).
  • Twenty-one patients (72.4%) were in stage III or IV at diagnosis.
  • The prognostic criteria include age of older than 25 years and a classification of stage III or IV disease.
  • [MeSH-major] Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. DNA Nucleotidylexotransferase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology






Advertisement